Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q


(Mark One)
☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 1-37774


AdvanSix Inc.
(Exact name of registrant as specified in its charter)


Delaware						81-2525089
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)


300 Kimball Drive, Suite 101, Parsippany, New Jersey						07054
(Address of principal executive offices)						(Zip Code)

(973) 526-1800

(Registrant’s telephone number, including area code)


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	ASIX	New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer ý	Accelerated filer o	Non-accelerated filer o	Smaller reporting company ☐
			Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ý

The Registrant had 26,731,009 shares of common stock, $0.01 par value, outstanding at October 25, 2024.

ADVANSIX INC.

FORM 10-Q

TABLE OF CONTENTS


Part I.	FINANCIAL INFORMATION

Item 1.	Financial Statements	3
	Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (unaudited)	3
	Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2024 and 2023 (unaudited)	4
	Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 (unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 (unaudited)	6
	Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2024 and 2023 (unaudited)	7
	Notes to Condensed Consolidated Financial Statements (unaudited)	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26
Item 4.	Controls and Procedures	26

Part II.	OTHER INFORMATION	27
Item 1.	Legal Proceedings	27
Item 1A.	Risk Factors	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 5.	Other Information	28
Item 6.	Exhibits	29
	Signature	30

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ADVANSIX INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(Dollars in thousands, except share and per share amounts)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Sales	$	398,187	$	322,907	$	1,188,495	$	1,151,391
Costs, expenses and other:
Costs of goods sold	340,885		314,785		1,046,860		1,004,844
Selling, general and administrative expenses	24,265		21,585		72,290		70,711
Interest expense, net	2,924		2,075		9,137		5,296
Other non-operating (income) expense, net	368		(5,485)		1,808		(6,918)
Total costs, expenses and other	368,442		332,960		1,130,095		1,073,933

Income (loss) before taxes	29,745		(10,053)		58,400		77,458
Income tax expense (benefit)	7,479		(2,076)		14,603		17,753
Net income (loss)	$	22,266	$	(7,977)	$	43,797	$	59,705

Earnings per common share
Basic	$	0.83	$	(0.29)	$	1.63	$	2.18
Diluted	$	0.82	$	(0.29)	$	1.61	$	2.12
Weighted average common shares outstanding
Basic	26,790,752		27,209,521		26,836,114		27,433,851
Diluted	27,204,714		27,209,521		27,209,680		28,193,721

See accompanying notes to Condensed Consolidated Financial Statements.

ADVANSIX INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited)

(Dollars in thousands)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Net income (loss)	$	22,266	$	(7,977)	$	43,797	$	59,705
Foreign exchange translation adjustment	(24)		197		(66)		39
Cash-flow hedges	—		—		7		(150)

Other comprehensive income (loss), net of tax	(24)		197		(59)		(111)
Comprehensive income (loss)	$	22,242	$	(7,780)	$	43,738	$	59,594

See accompanying notes to Condensed Consolidated Financial Statements.

ADVANSIX INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(Dollars in thousands, except share and per share amounts)


	September 30, 2024		December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$	17,298	$	29,768
Accounts and other receivables – net	149,058		165,393
Inventories – net	213,434		211,831
Taxes receivable	375		1,434
Other current assets	15,608		11,378
Total current assets	395,773		419,804
Property, plant and equipment – net	892,574		852,642
Operating lease right-of-use assets	90,740		95,805
Goodwill	56,192		56,192
Intangible assets	43,906		46,193
Other assets	31,050		25,384
Total assets	$	1,510,235	$	1,496,020

LIABILITIES
Current liabilities:
Accounts payable	$	207,272	$	259,068
Accrued liabilities	55,783		44,086
Income taxes payable	435		8,033
Operating lease liabilities – short-term	30,135		32,053
Deferred income and customer advances	1,517		15,678


Total current liabilities	295,142		358,918
Deferred income taxes	154,690		151,059
Operating lease liabilities – long-term	60,793		63,961
Line of credit – long-term	215,000		170,000

Postretirement benefit obligations	7,048		3,660
Other liabilities	11,154		9,185
Total liabilities	743,827		756,783

COMMITMENTS AND CONTINGENCIES (Note 9)

STOCKHOLDERS' EQUITY
Common stock, par value $0.01; 200,000,000 shares authorized; 32,982,868 shares issued and 26,730,739 outstanding at September 30, 2024; 32,598,946 shares issued and 26,750,471 outstanding at December 31, 2023	330		326
Preferred stock, par value $0.01; 50,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023	—		—
Treasury stock at par (6,252,129 shares at September 30, 2024; 5,848,475 shares at December 31, 2023)	(63)		(58)
Additional paid-in capital	134,735		138,046
Retained earnings	635,609		605,067
Accumulated other comprehensive loss	(4,203)		(4,144)
Total stockholders' equity	766,408		739,237
Total liabilities and stockholders' equity	$	1,510,235	$	1,496,020

See accompanying notes to Condensed Consolidated Financial Statements.

ADVANSIX INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(Dollars in thousands)


	Nine Months Ended September 30,
	2024		2023
Cash flows from operating activities:
Net income	$	43,797	$	59,705
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	57,197		54,337
Loss on disposal of assets	415		939
Deferred income taxes	3,638		1,069
Stock-based compensation	5,963		5,840
Amortization of deferred financing fees	464		464
Operational asset adjustments	1,200		(4,472)

Changes in assets and liabilities, net of business acquisitions:
Accounts and other receivables	15,069		42,185
Inventories	(1,603)		(14,082)
Taxes receivable	1,059		8,273
Accounts payable	(43,687)		(50,123)
Income taxes payable	(7,598)		2,136
Accrued liabilities	10,988		(7,787)
Deferred income and customer advances	(14,161)		(32,015)
Other assets and liabilities	(1,493)		(9,088)
Net cash provided by operating activities	71,248		57,381

Cash flows from investing activities:
Expenditures for property, plant and equipment	(99,373)		(69,025)


Other investing activities	(6,053)		(2,404)
Net cash used for investing activities	(105,426)		(71,429)

Cash flows from financing activities:



Borrowings from line of credit	311,500		371,000
Payments of line of credit	(266,500)		(316,000)

Principal payments of finance leases	(762)		(698)
Dividend payments	(12,858)		(12,354)
Purchase of treasury stock	(10,427)		(37,651)
Issuance of common stock	755		876

Net cash provided by financing activities	21,708		5,173

Net change in cash and cash equivalents	(12,470)		(8,875)
Cash and cash equivalents at beginning of period	29,768		30,985
Cash and cash equivalents at the end of period	$	17,298	$	22,110

Supplemental non-cash investing activities:
Capital expenditures included in accounts payable	$	15,018	$	21,188

Supplemental cash activities:
Cash paid for interest	$	7,711	$	4,998
Cash paid for income taxes	$	19,019	$	7,037

See accompanying notes to Condensed Consolidated Financial Statements.

ADVANSIX INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited)

(Dollars in thousands)


	Common Stock			Additional Paid-In Capital		Retained Earnings		Treasury Stock		Accumulated Other Comprehensive Income (Loss)		Total Equity
	Shares	Amount
Balance at December 31, 2023	32,598,946	$	326	$	138,046	$	605,067	$	(58)	$	(4,144)	$	739,237

Net loss	—	—		—		(17,396)		—		—		(17,396)
Comprehensive income
Foreign exchange translation adjustments	—	—		—		—		—		(15)		(15)
Cash-flow hedges	—	—		—		—		—		7		7

Other comprehensive loss, net of tax	—	—		—		—		—		(8)		(8)
Issuance of common stock	323,989	3		423		—		—		—		426
Purchase of treasury stock (260,464 shares)	—	—		(7,020)		—		(3)		—		(7,023)
Stock-based compensation	—	—		2,211		—		—		—		2,211
Dividends	—	—		163		(4,453)		—		—		(4,290)
Balance at March 31, 2024	32,922,935	329		133,823		583,218		(61)		(4,152)		713,157

Net income	—	—		—		38,927		—		—		38,927
Comprehensive income
Foreign exchange translation adjustments	—	—		—		—		—		(27)		(27)


Other comprehensive loss, net of tax	—	—		—		—		—		(27)		(27)
Issuance of common stock	36,653	1		—		—		—		—		1
Purchase of treasury stock (141,242 shares)	—	—		(3,360)		—		(2)		—		(3,362)
Stock-based compensation	—	—		2,193		—		—		—		2,193
Dividends	—	—		130		(4,422)		—		—		(4,292)
Balance at June 30, 2024	32,959,588	330		132,786		617,723		(63)		(4,179)		746,597

Net income	—	—		—		22,266		—		—		22,266
Comprehensive income
Foreign exchange translation adjustments	—	—		—		—		—		(24)		(24)


Other comprehensive loss, net of tax	—	—		—		—		—		(24)		(24)
Issuance of common stock	23,280	—		328		—		—		—		328
Purchase of treasury stock (1,948 shares)	—	—		(42)		—		—		—		(42)
Stock-based compensation	—	—		1,559		—		—		—		1,559
Dividends	—	—		104		(4,380)		—		—		(4,276)
Balance at September 30, 2024	32,982,868	$	330	$	134,735	$	635,609	$	(63)	$	(4,203)	$	766,408

ADVANSIX INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited)

(Dollars in thousands)


	Common Stock			Additional Paid-In Capital		Retained Earnings		Treasury Stock		Accumulated Other Comprehensive Income (Loss)		Total Equity
	Shares	Amount
Balance at December 31, 2022	31,977,593	$	320	$	174,585	$	567,517	$	(45)	$	(4,197)	$	738,180

Net income	—	—		—		34,954		—		—		34,954
Comprehensive income
Foreign exchange translation adjustments	—	—		—		—		—		(33)		(33)
Cash-flow hedges	—	—		—		—		—		(150)		(150)

Other comprehensive loss, net of tax	—	—		—		—		—		(183)		(183)
Issuance of common stock	555,249	5		617		—		—		—		622
Purchase of treasury stock (333,054 shares)	—	—		(13,496)		—		(3)		—		(13,499)
Stock-based compensation	—	—		2,013		—		—		—		2,013
Dividends	—	—		112		(4,132)		—		—		(4,020)
Balance at March 31, 2023	32,532,842	325		163,831		598,339		(48)		(4,380)		758,067

Net income	—	—		—		32,728		—		—		32,728
Comprehensive income
Foreign exchange translation adjustments	—	—		—		—		—		(125)		(125)


Other comprehensive loss, net of tax	—	—		—		—		—		(125)		(125)
Issuance of common stock	45,020	1		122		—		—		—		123
Purchase of treasury stock (410,862 shares)	—	—		(14,881)		—		(5)		—		(14,886)
Stock-based compensation	—	—		2,436		—		—		—		2,436
Dividends	—	—		198		(4,182)		—		—		(3,984)
Balance at June 30, 2023	32,577,862	326		151,706		626,885		(53)		(4,505)		774,359

Net income loss	—	—		—		(7,977)		—		—		(7,977)
Comprehensive income												—
Foreign exchange translation adjustments	—	—		—		—		—		197		197


Other comprehensive income, net of tax	—	—		—		—		—		197		197
Issuance of common stock	19,153	—		131		—		—		—		131
Purchase of treasury stock (266,959 shares)	—	—		(9,264)		—		(2)		—		(9,266)
Stock-based compensation	—	—		1,391		—		—		—		1,391
Dividends	—	—		1		(4,351)		—		—		(4,350)
Balance at September 30, 2023	32,597,015	$	326	$	143,965	$	614,557	$	(55)	$	(4,308)	$	754,485

See accompanying notes to Condensed Consolidated Financial Statements.

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

1. Organization, Operations and Basis of Presentation

Description of Business

AdvanSix Inc. ("AdvanSix," the "Company," "we" or "our") is a diversified chemistry company playing a critical role in global supply chains, innovating and delivering essential products for our customers in a wide variety of end markets and applications that touch people’s lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. Our reliable and sustainable supply of quality products emerges from the integrated value chain of our five U.S.-based manufacturing facilities. AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, plant nutrients and chemical intermediates, guided by our core values of Safety, Integrity, Accountability and Respect.

Basis of Presentation

The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of September 30, 2024, and its results of operations for the three and nine months ended September 30, 2024 and 2023 and cash flows for the nine months ended September 30, 2024 and 2023. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"). All intercompany transactions have been eliminated.

Certain prior period amounts have been reclassified for consistency with the current period presentation.

It is our practice to establish actual quarterly closing dates using a predetermined fiscal calendar, which requires our businesses to close their books on a Saturday in order to minimize the potentially disruptive effects of quarterly closing on our business processes. Historically, the effects of this practice have generally not been significant to reported results for any quarter and only existed within a reporting year. In the event that differences in actual closing dates are material to year-over-year comparisons of quarterly or year-to-date results, we will provide the appropriate disclosures. Our actual closing dates for the three and nine months ended September 30, 2024 and 2023 were September 28, 2024 and September 30, 2023, respectively.

Liabilities to creditors to whom we have issued checks that remained outstanding at September 30, 2024 and December 31, 2023 aggregated to $2.4 million and $2.9 million, respectively, and were included in Cash and cash equivalents and Accounts payable in the Condensed Consolidated Balance Sheets.

The Company's Board of Directors (the "Board") has authorized share repurchase programs to repurchase shares of the Company's common stock as follows:


Date of Authorization	Authorized Amount (millions)		Authorized Amount Remaining as of September 30, 2024 (millions)
May 4, 2018	$	75.0	$	—
February 22, 2019	75.0		—
February 17, 2023	75.0		62.0
Totals	$	225.0	$	62.0

Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including through the use of trading plans intended to qualify under Rule

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time. The par value of the shares repurchased is applied to Treasury stock and the excess of the purchase price over par value is applied to Additional paid-in capital.

As of September 30, 2024, the Company has repurchased a total of 6,252,129 shares of common stock, including 1,006,673 shares withheld to cover tax withholding obligations in connection with the vesting of awards, for an aggregate of $192.4 million at a weighted average market price of $30.78 per share. As of September 30, 2024, $62.0 million remained available for share repurchases under the current authorization. During the period October 1, 2024 through October 25, 2024, no additional shares were repurchased for tax withholding obligations or under the currently authorized repurchase program.

2. Recent Accounting Pronouncements

Recent Accounting Pronouncements – The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations.

On December 13, 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this ASU require that public business entities, on an annual basis, disclose specific categories in the rate reconciliation and provide additional information for reconciling items that are equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate. The amendments also require that the Company disclose the following (net of refunds received): (1) the amount of income taxes paid disaggregated by federal (national), state, and foreign taxes and (2) the amount of income taxes paid disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than 5 percent of total income taxes paid. Additionally, the amendments in this update eliminate the requirement for all entities to disclose the nature and estimate of the range of the reasonably possible change in the unrecognized tax benefits balance in the next 12 months or to make a statement that an estimate of the range cannot be made, and remove the requirement to disclose the cumulative amount of each type of temporary difference when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries and corporate joint ventures. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption of the amendments in this update are permitted for annual financial statements that have not yet been issued. The Company is evaluating the pronouncement and does not expect adoption to have a material impact on the Company's consolidated financial position or results of operations.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this ASU require incremental disclosures about the Company's reportable segments, but do not change the definition of a segment or the guidance for determining reportable segments. The incremental disclosures should include (1) significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, (2) an amount for other segment items by reportable segment and a description of its composition, (3) profit or loss and assets currently required by Topic 280 in interim periods, (4) clarification if the CODM uses more than one measure of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources and (5) the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. The guidance is effective for public entities with fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Additionally, public entities should apply the amendments retrospectively to all prior periods presented in the financial statements, unless impractical. The Company is evaluating the pronouncement and does not expect adoption to have a material impact on the Company's consolidated financial position or results of operations.

3. Revenues

Revenue Recognition

AdvanSix serves around 400 customers annually, primarily in the United States, spanning a wide variety of industries worldwide. For each of the three months ended September 30, 2024 and 2023, the Company's ten largest customers accounted for approximately 41% of total sales. For the nine months ended September 30, 2024 and 2023, the Company's ten largest customers accounted for approximately 38% and 39% of total sales, respectively.

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

We typically sell to customers under master service agreements, with primarily one-year terms, or by purchase orders. We have historically experienced low customer turnover and have long-standing customer relationships, which span decades. Our largest customer is Shaw Industries Group, Inc. (“Shaw”), a significant consumer of caprolactam and Nylon 6 resin, to whom we sell under a long-term agreement. For the three months ended September 30, 2024 and 2023 the Company's sales to Shaw were 10% and 12% of our total sales, respectively. For the nine months ended September 30, 2024 and 2023, the Company's sales to Shaw were 9% and 11% of our total sales, respectively.

The Company's revenue by product line, and related approximate percentage of total sales, for the three and nine months ended September 30, 2024 and 2023 were as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
Nylon	$	93,693	24%	$	86,056	27%	$	281,299	24%	$	278,381	24%
Caprolactam	76,338		19%	68,795		21%	219,117		18%	215,867		19%
Ammonium Sulfate *	107,668		27%	79,067		24%	332,604		28%	332,224		29%
Chemical Intermediates *	120,488		30%	88,989		28%	355,475		30%	324,919		28%
Total	$	398,187	100%	$	322,907	100%	$	1,188,495	100%	$	1,151,391	100%

* The previously reported amounts have been corrected for a misclassification which overstated Ammonium Sulfate and understated Chemical Intermediates by $5.5 million (2%) and $26.6 million (2%) for the three and nine months ended September 30, 2023, respectively. Total revenue amounts were not impacted for either period.

The Company's revenues by geographic area, and related approximate percentage of total sales, for the three and nine months ended September 30, 2024 and 2023 were as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
United States	$	339,895	85%	$	264,858	82%	$	1,026,342	86%	$	953,392	83%
International	58,292		15%	58,049		18%	162,153		14%	197,999		17%
Total	$	398,187	100%	$	322,907	100%	$	1,188,495	100%	$	1,151,391	100%

Deferred Income and Customer Advances

The Company defers revenues when cash payments are received in advance of our performance. Below is a roll-forward of Deferred income and customer advances for the nine months ended September 30, 2024:



Opening balance January 1, 2024	$	15,678
Additional cash advances	1,453
Less amounts recognized in revenues	(15,614)
Ending balance September 30, 2024	$	1,517

The Company expects to recognize as revenue the September 30, 2024 ending balance of Deferred income and customer advances within one year or less.

4. Earnings Per Share

The computation of basic and diluted earnings per share ("EPS") is based on Net income (loss) divided by the basic weighted average number of common shares outstanding and diluted weighted average number of common shares outstanding, respectively. The details of the basic and diluted EPS calculations for the three and nine months ended September 30, 2024 and 2023 were as follows:

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Basic
Net income (loss)	$	22,266	$	(7,977)	$	43,797	$	59,705
Weighted average common shares outstanding	26,790,752		27,209,521		26,836,114		27,433,851
EPS – Basic	$	0.83	$	(0.29)	$	1.63	$	2.18
Diluted
Dilutive effect of equity awards and other stock-based holdings	413,962		—		373,566		759,870
Weighted average common shares outstanding	27,204,714		27,209,521		27,209,680		28,193,721
EPS – Diluted	$	0.82	$	(0.29)	$	1.61	$	2.12

Diluted EPS is computed based upon the weighted average number of common shares outstanding for the period plus the dilutive effect of common stock equivalents using the treasury stock method and the average market price of our common stock for the period.

The diluted EPS calculations exclude the effect of stock options when the options’ assumed proceeds exceed the average market price of the common shares during the period. The anti-dilutive common stock equivalents outstanding at the three and nine months ended September 30, 2024 and 2023 were as follows:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Options and stock equivalents	573,586	498,652	976,699	447,950

Dividend activity for the three and nine months ended September 30, 2024 and 2023 was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Cash dividends declared per share	$	0.16	$	0.16	$	0.48	$	0.45
Aggregate dividends paid to shareholders	$	4,276	$	4,349	$	12,858	$	12,354

5. Accounts and Other Receivables – Net


	September 30, 2024		December 31, 2023
Accounts receivables	$	142,598	$	155,267
Other	6,982		10,959
Total accounts and other receivables	149,580		166,226
Less – allowance for doubtful accounts	(522)		(833)
Total accounts and other receivables – net	$	149,058	$	165,393

6. Inventories

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)


	September 30, 2024		December 31, 2023
Raw materials	$	119,876	$	159,240
Work in progress	65,980		54,936
Finished goods	58,639		61,891
Spares and other	32,989		30,931
	277,484		306,998
Reduction to LIFO cost basis	(64,050)		(95,167)
Total inventories	$	213,434	$	211,831

Substantially all of the Company’s inventories at September 30, 2024 and December 31, 2023 are valued at the lower of cost or market using the last-in, first-out (“LIFO”) method. However, approximately 8% was valued at average cost using the first-in, first-out (“FIFO”) method at September 30, 2024.

The excess of replacement cost over the carrying value of total inventories subject to LIFO was $65.1 million and $65.3 million at September 30, 2024 and December 31, 2023, respectively.

7. Leases

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use assets ("ROU"), Operating lease liabilities – short-term, and Operating lease liabilities – long-term in our Condensed Consolidated Balance Sheets. Finance leases are included in Property, plant and equipment – net, Accounts payable, and Other liabilities in our Condensed Consolidated Balance Sheets.

The components of lease expense were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Finance lease cost:
Amortization of right-of-use asset	$	269	$	237	$	776	$	675
Interest on lease liabilities	43		28		120		69
Total finance lease cost	312		265		896		744
Operating lease cost	10,305		12,032		32,789		34,873
Short-term lease cost	1,177		1,572		3,511		4,109

Total lease cost	$	11,794	$	13,869	$	37,196	$	39,726

As of September 30, 2024, we have additional operating leases that have not yet commenced for approximately $93.1 million. These leases are expected to commence during the second half of 2024 and in 2025 with lease terms of up to 6 years.

8. Goodwill and Intangible Assets

Intangible assets with finite lives acquired through a business combination are recorded at fair value, less accumulated amortization. Customer relationships and trade-names are amortized on a straight-line basis over their expected useful lives of 15 to 20 years and 5 years, respectively.

Goodwill

There was no change in the carrying amount of goodwill for the nine months ended September 30, 2024.

Finite-Lived Intangible Assets

Intangible assets subject to amortization were as follows:

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)


	September 30, 2024						December 31, 2023
	Gross Carrying Amount		Accumulated Amortization		Net Book Value		Gross Carrying Amount		Accumulated Amortization		Net Book Value
Customer relationships	$	36,820	$	(5,190)	$	31,630	$	36,820	$	(3,760)	$	33,060
Licenses	18,451		(6,688)		11,763		18,451		(5,996)		12,455
Trade names	1,100		(587)		513		1,100		(422)		678
Total	$	56,371	$	(12,465)	$	43,906	$	56,371	$	(10,178)	$	46,193

For each of the three months ended September 30, 2024 and September 30, 2023, the Company recorded amortization expense on intangible assets of $0.8 million. For each of the nine months ended September 30, 2024 and September 30, 2023, the Company recorded amortization expense on intangible assets of $2.3 million.

9. Commitments and Contingencies

The Company is subject to a number of lawsuits, investigations and disputes, some of which may involve substantial amounts claimed, arising out of the conduct of the Company or other third-parties in the normal and ordinary course of business. A liability is recognized for any contingency that is probable of occurrence and reasonably estimable. The Company continually assesses the likelihood of adverse judgments or outcomes in these matters, as well as potential ranges of possible losses, based on an analysis of each matter with the assistance of legal counsel and, if applicable, other experts.

Given the uncertainty inherent in such lawsuits, investigations and disputes, the Company does not believe it is possible to develop estimates of reasonably possible loss in excess of current accruals for these matters. Considering the Company’s past experience and existing accruals, the Company does not expect the outcome of these matters, either individually or in the aggregate, to have a material adverse effect on the Company’s consolidated financial position or results of operations. Potential liabilities are subject to change due to new developments, changes in settlement strategy or the impact of evidentiary requirements, which could cause the Company to pay damage awards or settlements (or become subject to equitable remedies) that could have a material adverse effect on the Company’s consolidated results of operations, balance sheet and/or operating cash flows in the periods recognized or paid.

We assumed from Honeywell International Inc. ("Honeywell") all health, safety and environmental (“HSE”) liabilities and compliance obligations related to the past and future operations of our current business as of the spin-off, as well as all HSE liabilities associated with the three manufacturing locations assumed from Honeywell that are used in our current operations, including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to have a material adverse effect on the Company's consolidated financial position or results of operations.

10. Income Taxes

The provision (benefit) for income taxes was $7.5 million and ($2.1 million) for the three months ended September 30, 2024 and 2023, respectively, resulting in an effective tax rate of 25.1% and 20.7%, respectively. The provision for income taxes was $14.6 million and $17.8 million for the nine months ended September 30, 2024 and 2023, respectively, resulting in an effective tax rate of 25.0% and 22.9%, respectively.

The Company’s provision (benefit) for income taxes in interim periods is computed by applying an estimated annual effective tax rate against Income before taxes for the period in addition to recording any tax effects of discrete items for the quarter. The Company’s effective tax rate for the three and nine months ended September 30, 2024 and 2023 differed from the U.S. federal statutory rate, due primarily to the impacts of state taxes and executive compensation deduction limitations, offset by tax credits and the foreign-derived intangible income deduction. In 2024, the Company recorded discrete tax adjustments related to the vesting of equity compensation, changes to state tax legislation, and return to provision adjustments related to the filing of the Company's 2023 U.S. federal income tax return which resulted in a net 3.3% increase to the quarterly effective tax rate and a net 1.5% increase to the year-to-date effective tax rate. Additionally for 2023, discrete tax adjustments relating to the vesting of equity compensation, changes in state tax legislation, and return to provision adjustments related to the filing of the Company's

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

2022 U.S. federal income tax return resulted in a net 4.4% increase to the quarterly effective tax rate and a net 1.6% decrease to the year-to-date effective tax rate.

11. Fair Value Measurements

Financial and non-financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The pension plan assets are invested in collective investment trust funds. These investments are measured at fair value using the net asset value per share as a practical expedient. Investments valued using the net asset value method (NAV) (or its equivalent) practical expedient are excluded from the fair value hierarchy disclosure.

The Company’s Condensed Consolidated Balance Sheets also include Cash and cash equivalents, Accounts receivable and Accounts payable all of which are recorded at amounts which approximate fair value.

The Company also has assets that are required to be recorded at fair value on a non-recurring basis. These assets are evaluated when certain triggering events occur (including a decrease in estimated future cash flows) that indicate the asset should be evaluated for impairment which could result in such assets being measured at fair value. Goodwill must be evaluated at least annually. Our annual evaluation occurred on October 28, 2023 and we concluded that an impairment for goodwill did not occur.

12. Supplier Finance Programs

The Company has entered into a supply chain finance program with a financial intermediary providing participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. AdvanSix’s responsibility is limited to making payments to the intermediary based upon payment terms negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. The Company’s payment terms with suppliers are consistent, regardless of whether a vendor participates in the supply chain finance program or not. All related agreements are terminable by either party upon at least 30 days’ notice.

The total amount due to the financial intermediaries to settle supplier invoices under the supplier finance programs was approximately $15 million as of September 30, 2024 and approximately $17 million as of December 31, 2023. These amounts outstanding are included in Accounts payable.

13. Subsequent Events

As announced on November 1, 2024, the Board declared a quarterly cash dividend of $0.16 per share on the Company's common stock, payable on November 26, 2024 to stockholders of record as of the close of business on November 12, 2024.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of the Company’s financial condition and results of operations, which we refer to as our “MD&A,” should be read in conjunction with the Condensed Consolidated Financial Statements and the notes thereto contained in this Quarterly Report on Form 10-Q (this "Form 10-Q"), as well as the MD&A section included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on February 16, 2024 (the “2023 Form 10-K”). Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Actual results and the timing of events may differ materially from those contained in these forward-looking statements due to a number of factors that can affect our performance in both the near- and long-term, including those incorporated by reference in Item 1A of Part II of this Form 10-Q as such factors may be revised or supplemented in subsequent filings with the SEC, as well as those discussed in the section entitled “Note Regarding Forward-Looking Statements” below.

Note Regarding Forward-Looking Statements

All statements other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this MD&A regarding our financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this Form 10-Q, words such as "expect," “anticipate,” "estimate," "outlook," "project," "strategy," "intend," "plan," "target," "goal," "may," "will," "should," and “believe,” and other variations or similar terminology and expressions identify forward-looking statements. Although we believe forward-looking statements are based upon reasonable assumptions, such statements involve known and unknown risks, uncertainties and other factors, many of which are beyond our control and difficult to predict, which may cause the actual results or performance of the Company to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: general economic and financial conditions in the U.S. and globally; the potential effects of inflationary pressures, labor market shortages and supply chain issues; instability or volatility in financial markets or other unfavorable economic or business conditions caused by geopolitical concerns, including as a result of the political and policy uncertainties with the approaching U.S. Presidential election, and the conflict between Russia and Ukraine, the conflict in Israel and Gaza and the possible expansion of such conflicts; the effect of any of the foregoing on our customers’ demand for our products and our suppliers’ ability to manufacture and deliver our raw materials, including implications of reduced refinery utilization in the U.S.; our ability to sell and provide our goods and services; the ability of our customers to pay for our products; any closures of our and our customers’ offices and facilities; risks associated with increased phishing, compromised business emails and other cybersecurity attacks, data privacy incidents and disruptions to our technology infrastructure; risks associated with operating with a reduced workforce; risks associated with our indebtedness including compliance with financial and restrictive covenants, and our ability to access capital on reasonable terms, at a reasonable cost, or at all, due to economic conditions or otherwise; the impact of scheduled turnarounds and significant unplanned downtime and interruptions of production or logistics operations as a result of mechanical issues or other unanticipated events such as fires, severe weather conditions, natural disasters, pandemics and, geopolitical conflicts and related events; price fluctuations, cost increases and supply of raw materials; our operations and growth projects requiring substantial capital; growth rates and cyclicality of the industries we serve including global changes in supply and demand; failure to develop and commercialize new products or technologies; loss of significant customer relationships; adverse trade and tax policies; extensive environmental, health and safety laws that apply to our operations; hazards associated with chemical manufacturing, storage and transportation; litigation associated with chemical manufacturing and our business operations generally; inability to acquire and integrate businesses, assets, products or technologies; protection of our intellectual property and proprietary information; prolonged work stoppages as a result of labor difficulties or otherwise; failure to maintain effective internal controls; our ability to declare and pay quarterly cash dividends and the amounts and timing of any future dividends; our ability to repurchase our common stock and the amount and timing of any future repurchases; disruptions in supply chain, transportation and logistics; potential for uncertainty regarding qualification for tax treatment of our spin-off; fluctuations in our stock price; and changes in laws or regulations applicable to our business. Forward-looking statements are not guarantees of future performance and actual results could differ materially from those contemplated by the forward-looking statements as a result of a number of risks, uncertainties and other factors including those noted above and those detailed in Item 1A of Part I and elsewhere in our 2023 Form 10-K, and subsequent reports filed with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. We do not undertake to update or revise any of our forward-looking statements.

Business Overview

AdvanSix is a diversified chemistry company playing a critical role in global supply chains, innovating and delivering essential products for our customers in a wide variety of end markets and applications that touch people’s lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. Our reliable

and sustainable supply of quality products emerges from the integrated value chain of our five U.S.-based manufacturing facilities. AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, plant nutrients and chemical intermediates, guided by our core values of Safety, Integrity, Accountability and Respect. Our four key product lines are as follows:

•Nylon Solutions

◦Nylon – We sell our Nylon 6 resin globally, primarily under the Aegis® brand name. Nylon 6 is a polymer resin which is a synthetic material used by our customers to produce fibers, filaments, engineered plastics and films that, in turn, are used in such end-products as carpets, automotive and electric components, sports apparel, food packaging and other industrial applications.

◦Caprolactam – Caprolactam is the key monomer used in the production of Nylon 6 resin. We internally polymerize caprolactam into Aegis® Nylon 6 Resins, and we also market and sell the caprolactam that is not consumed internally to customers who use it to manufacture polymer resins to produce fibers, compounds and other nylon products. Our Hopewell, VA manufacturing facility is one of the world’s largest single-site producers of caprolactam as of September 30, 2024.

•Ammonium Sulfate – Our ammonium sulfate is used by customers as a fertilizer containing nitrogen and sulfur, two key plant nutrients. Ammonium sulfate fertilizer is derived from the integrated operations at the Hopewell manufacturing facility. Because of our Hopewell facility’s size, scale and technology design, we are the world’s largest single-site producer of ammonium sulfate fertilizer as of September 30, 2024. We market and sell ammonium sulfate primarily to North American and South American distributors, farm cooperatives and retailers to fertilize crops.

•Chemical Intermediates – We manufacture, market and sell a number of other chemical intermediate products that are derived from the manufacturing processes within our integrated supply chain. Most significant is acetone which is used by our customers in the production of adhesives, paints, coatings, solvents, herbicides and engineered plastic resins. Other intermediate chemicals that we manufacture, market and sell include phenol, alpha-methylstyrene (“AMS”), cyclohexanone, 2-pentanone oxime, cyclohexanol, sulfuric acid, ammonia and carbon dioxide. With the acquisition of U.S. Amines Limited (“U.S. Amines”), we now produce alkyl and specialty amines serving high-value end markets such as agrochemicals and pharmaceuticals.

Global demand for Nylon 6 resin spans a variety of end-uses such as textiles, engineered plastics, industrial filament, food and industrial films, and carpet. The market growth typically tracks global GDP growth over the long-term but varies by end-use. We produce and sell caprolactam as a commodity product and produce and sell our Nylon 6 resin as both a commoditized and differentiated resin product. Our results of operations are primarily driven by production volume and the spread between the sales prices of our products and the costs of the underlying raw materials built into market-based and value-based pricing models. The global prices for nylon resin typically track a spread over the price of caprolactam, which in turn tracks as a spread over benzene because the key feedstock materials for caprolactam, phenol or cyclohexane, are derived from benzene. This price spread has historically experienced cyclicality as a result of global changes in supply and demand. Generally, Nylon 6 resin prices track the cyclicality of caprolactam prices, although prices set above the spread are achievable when nylon resin manufacturers, like AdvanSix, formulate and produce differentiated nylon resin products for current and new customer applications, such as our wire and cable and co-polymer offerings.

Global prices for ammonium sulfate fertilizer are influenced by several factors including the price of urea, which sets the nutrient value for nitrogen as it is the most widely used source of nitrogen-based fertilizer in the world. Other global factors driving ammonium sulfate fertilizer demand are general agriculture trends, including planted acres and the price of crops. Our ammonium sulfate product is positioned with the added value proposition of sulfur nutrition to increase yields of key crops. In addition, due to its nutrient density, the typical ammonium sulfate product delivers pound for pound the most readily available sulfur and nitrogen to crops as compared to other fertilizers. We also directly supply packaged ammonium sulfate to customers, primarily in North and South America, and have diversified and optimized our offerings to include spray-grade adjuvants to support crop protection, as well as other specialty fertilizers and products for industrial use.

We produce ammonium sulfate fertilizer continuously throughout the year as part of our manufacturing process, but quarterly sales fluctuate reflecting both geographical and product sales mix considerations based on the timing and length of the growing seasons in North and South America. North American ammonium sulfate demand and pricing, particularly for our higher-value granular product, are typically strongest during second quarter fertilizer application and then typically decline seasonally with new season fill in the third quarter. Ammonium sulfate industry prices in the corn belt have declined approximately 10% from the second quarter to the third quarter, on average, since 2016. Due to the ammonium sulfate fertilizer sales cycle, we occasionally build up higher inventory balances because our production is continuous and not tied to seasonal demand for fertilizers. Sales of most of our other products have generally been subject to minimal, or no, seasonality.

We also manufacture, market and sell a number of chemical intermediate products that are derived from the manufacturing processes within our integrated supply chain. Most significant is acetone, the price of which is influenced by its own supply and demand dynamics but can also be influenced by the underlying move in propylene input costs. Our differentiated product offerings include high-purity applications and high-value intermediates including our U.S. Amines portfolio as well as our oximes-based EZ-Blox™ anti-skinning agent used in paints and Nadone® cyclohexanone, which is a solvent used in various high-value applications.

We seek to run our production facilities on a nearly continuous basis for maximum efficiency as several of our intermediate products are key feedstock materials for other products in our integrated manufacturing chain. While our integration, scale and range of product offerings make us one of the most efficient manufacturers in our industry, these attributes also expose us to increased risk associated with material disruptions at any one of our production facilities or logistics operations which could impact the overall manufacturing supply chain. Further, although we believe that our sources of supply for our raw materials, including cumene, natural gas and sulfur, are generally robust, it is difficult to predict the impact that shortages, increased costs and related supply chain logistics considerations may have in the future. In order to mitigate the risk of unplanned interruptions, we schedule several planned plant turnarounds each year to conduct routine and major maintenance across our facilities. We also utilize maintenance excellence and mechanical integrity programs, targeted buffer inventory of intermediate chemicals necessary for our manufacturing process, and co-producer swap arrangements, which are intended to mitigate the extent of any production losses as a result of planned and unplanned downtime; however, the mitigation of all or part of any such production impact cannot be assured.

Recent Developments

Business Operations

In October 2024, additional required maintenance at our Hopewell, VA manufacturing site resulted in a delayed ramp to full operating rates following our multi-site planned plant turnaround. The Company expects an incremental approximately $17 million unfavorable impact to pre-tax income in the fourth quarter 2024, inclusive of $10 million related to fixed cost absorption and higher maintenance expense, and $7 million of lost sales. The unplanned interruption did not have any impact on the third quarter 2024 financial results.

In January 2024, the Company experienced a process-based operational disruption at its Frankford, Pennsylvania manufacturing site temporarily reducing phenol and acetone production at the facility, as well as production at its Hopewell and Chesterfield, Virginia facilities. As a result of a delayed ramp to targeted utilization rates, the Company recognized an unfavorable impact to pre-tax income in the first quarter 2024 of approximately $27 million, comprised of the impact of lost sales and other additional costs including purchases of replacement product and incremental plant spend. The Company returned to targeted utilization rates at its Frankford, Pennsylvania manufacturing site, as well as across its value chain, prior to the end of the first quarter of 2024.

Chesterfield, VA Collective Bargaining Agreement

On May 9, 2024, the Company’s Chesterfield bargaining unit, represented by the Teamsters Local 592, ratified a new five-year labor agreement in advance of the prior agreement’s expiration date of May 14, 2024. The ratified labor agreement affected approximately 160 workers at the Company’s manufacturing facility in Chesterfield, Virginia.

Succession of Senior Vice President and Chief Financial Officer

Michael Preston retired as the Company's Senior Vice President and Chief Financial Officer, effective as of October 1, 2024, but will remain at the Company through year-end 2024 to help facilitate the transition of his responsibilities to his successor. Effective as of October 1, 2024, the Board of Directors has appointed Siddharth Manjeshwar as Senior Vice President and Chief Financial Officer to succeed Mr. Preston.

Results of Operations

(Dollars in thousands, unless otherwise noted)

Sales


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Sales	$	398,187	$	322,907	$	1,188,495	$	1,151,391
% change compared with prior year period	23.3%				3.2%

The change in sales compared to the prior year period is attributable to the following:


	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024
Volume	10.6%	2.6%
Price	12.7%	0.6%

	23.3%	3.2%

Sales increased in the three months ended September 30, 2024 compared to the prior year period by $75.3 million (approximately 23%) due primarily to (i) increased volume (approximately 11%) primarily driven by higher sales of all product lines, particularly ammonium sulfate supported by sulfur nutrition demand, (ii) favorable raw material pass-through pricing (approximately 8%) as a result of a net cost increase in benzene and propylene (inputs to cumene which is a key feedstock to our products), and (iii) net favorable market-based pricing (approximately 5%) including continued strength in acetone, as well as ammonium sulfate as growers seeking to maximize crop yields continue to recognize the benefits of sulfur nutrition.

Sales increased in the nine months ended September 30, 2024 compared to the prior year period by $37.1 million (approximately 3%) due primarily to (i) increased volume (approximately 3%) primarily driven by higher sales of our nylon and ammonium sulfate product lines with strength in the second and third quarters more than offsetting lost sales resulting from the process-based operational disruption at the Frankford site in the first quarter, and (ii) net pricing (approximately 1%) reflecting favorable raw material pass-through pricing partially offset by lower market-based pricing.

Costs of Goods Sold


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Costs of goods sold	$	340,885	$	314,785	$	1,046,860	$	1,004,844
% change compared with prior year period	8.3%				4.2%
Gross Margin percentage	14.4%		2.5%		11.9%		12.7%

Costs of goods sold increased in the three months ended September 30, 2024 compared to the prior year period by $26.1 million (approximately 8%) due primarily to (i) increased prices of raw materials (approximately 8%) and (ii) increased sales volume (approximately 7%), partially offset by the favorable timing of planned plant turnarounds year-over-year (approximately 8%).

Costs of goods sold increased in the nine months ended September 30, 2024 compared to the prior year period by $42.0 million (approximately 4%) due primarily to (i) increased sales volume (approximately 4%), (ii) the impact of lower production volumes (approximately 2%) primarily driven by the process-based operational disruption at the Frankford, Pennsylvania manufacturing site and (iii) increased prices of raw materials (approximately 1%), partially offset by the favorable timing of the planned plant turnarounds year-over-year (approximately 2%).

Gross margin percentage increased in the three months ended September 30, 2024 compared to the prior year period (approximately 12%) due primarily to (i) favorable timing of the planned plant turnarounds year-over-year (approximately 6%), (ii) the impact of market-based pricing, net of raw material costs (approximately 4%), and (iii) higher sales volume (approximately 3%).

Gross margin percentage decreased in the nine months ended September 30, 2024 compared to the prior year period (approximately 1%) due primarily to (i) the net impact of lower production volumes (approximately 2%) driven primarily by the process-based operational disruption at the Frankford, Pennsylvania manufacturing site and (ii) the impact of market-based pricing, net of raw material costs (approximately 1%), partially offset by the favorable timing of the planned plant turnarounds year-over-year (approximately 2%) and decreased plant costs (approximately 1%).

Selling, General and Administrative Expenses


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Selling, general and administrative expenses	$	24,265	$	21,585	$	72,290	$	70,711
Percentage of Sales	6.1%		6.7%		6.1%		6.1%

Selling, general and administrative expenses increased by $2.7 million in the three months ended September 30, 2024 compared to the prior year period due primarily to increased incentive-based compensation expense and enterprise resource planning system expense partially offset by moderated functional support costs.

Selling, general and administrative expenses increased by $1.6 million in the nine months ended September 30, 2024 compared to the prior year period due to increased incentive-based compensation expense and enterprise resource planning system expense partially offset by lower bad debt expense and moderated functional support costs.

Income Tax Expense


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Income tax expense (benefit)	$	7,479	$	(2,076)	$	14,603	$	17,753
Effective tax rate	25.1%		20.7%		25.0%		22.9%

The Company's effective tax rate for the three months ended September 30, 2024 was higher than the prior year period due primarily to the Loss before taxes recorded in the prior year period and a related reduction in the foreign-derived intangible income benefit that collectively reduced the 2023 quarterly rate by approximately 6%. The Company's effective tax rate for the nine months ended September 30, 2024 was higher than the prior year period due primarily to the impacts of discrete adjustments in each respective period, which represented a net increase in the quarterly rate of approximately 3.1% as compared to the prior year period. This increase in the effective tax rate was attributable to the return to provision adjustments related to the filing of the Company's U.S. federal income tax returns and a reduction in the benefit associated with vesting of equity compensation, net of a decrease in effective tax rate associated with state legislation enacted during the period ended September 30, 2024.

Net Income


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Net income (loss)	$	22,266	$	(7,977)	$	43,797	$	59,705

As a result of the factors described above, Net income (loss) was $22.3 million for the three months ended September 30, 2024 as compared to $(8.0) million in the corresponding prior year period.

As a result of the factors described above, Net income was $43.8 million for the nine months ended September 30, 2024 as compared to $59.7 million in the corresponding prior year period.

Non-GAAP Measures

(Dollars in thousands, unless otherwise noted)

The following tables set forth the non-GAAP financial measures of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net income and Adjusted Earnings Per Share. Adjusted EBITDA is defined as Net income before Interest, Income taxes, Depreciation and amortization, Non-cash stock-based compensation, Non-recurring, unusual or extraordinary expenses, Non-cash amortization from acquisitions and One-time merger and acquisition costs. Adjusted EBITDA Margin is equal to Adjusted EBITDA divided by Sales. The Company believes these non-GAAP financial measures provide meaningful supplemental information as they are used by the Company’s management to evaluate the Company’s operating performance, enhance a reader’s understanding of the financial performance of the Company, and facilitate a better comparison among fiscal periods and performance relative to its competitors, as the non-GAAP measures exclude items that management believes do not reflect the Company’s ongoing operations.

These non-GAAP results are presented for supplemental informational purposes only and should not be considered a substitute for the financial information presented in accordance with U.S. GAAP. Non-GAAP financial measures should be read only in conjunction with the comparable U.S. GAAP financial measures. The Company's non-GAAP measures may not be comparable to other companies' non-GAAP measures.

The following is a reconciliation between the non-GAAP financial measures of Adjusted Net income, Adjusted EBITDA and Adjusted EBITDA Margin to their most directly comparable U.S. GAAP financial measure:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Net income (loss)	$	22,266	$	(7,977)	$	43,797	$	59,705
Non-cash stock-based compensation	1,559		1,391		5,963		5,840
Non-recurring, unusual or extraordinary (income) expense*	—		(4,472)		1,200		(4,472)
Non-cash amortization from acquisitions	531		532		1,595		1,596
Non-recurring M&A costs	—		—		—		—
Income tax expense (benefit) relating to reconciling items	(367)		776		(1,594)		(157)
Adjusted Net income (loss) (non-GAAP)	23,989		(9,750)		50,961		62,512
Interest expense, net	2,924		2,075		9,137		5,296
Income tax expense (benefit) - Adjusted	7,846		(2,852)		16,197		17,911
Depreciation and amortization - Adjusted	18,402		17,848		55,602		52,741
Adjusted EBITDA (non-GAAP)	$	53,161	$	7,321	131,897		138,460



Sales	$	398,187	$	322,907	$	1,188,495	$	1,151,391

Adjusted EBITDA Margin** (non-GAAP)	13.4%		2.3%		11.1%		12.0%

* 2024 includes a pre-tax loss of approximately $1.2 million from the reduction of the Company's anticipated receivable related to the gain on the termination fee recorded upon the exit from the Oben Holding Group S.A. alliance during the third quarter of 2023. During 2023, there were several transactions including the exit from the Oben Holding Group S.A. alliance, licensee exit of legacy technology and exit of certain low-margin oximes products that resulted in a $4.5 million net pre-tax loss.

** Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Sales

The following is a reconciliation between the non-GAAP financial measures of Adjusted Earnings Per Share to its most directly comparable U.S. GAAP financial measure:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023

Net income (loss)	$	22,266	$	(7,977)	$	43,797	$	59,705
Adjusted Net income (loss) (non-GAAP)	23,989		(9,750)		50,961		62,512


Weighted-average number of common shares outstanding - basic	26,790,752		27,209,521		26,836,114		27,433,851
Dilutive effect of equity awards and other stock-based holdings	413,962		—		373,566		759,870
Weighted-average number of common shares outstanding - diluted	27,204,714		27,209,521		27,209,680		28,193,721

EPS - Basic	$	0.83	$	(0.29)	$	1.63	$	2.18
EPS - Diluted	$	0.82	$	(0.29)	$	1.61	$	2.12
Adjusted EPS - Basic (non-GAAP)	$	0.90	$	(0.36)	$	1.90	$	2.28
Adjusted EPS - Diluted (non-GAAP)	$	0.88	$	(0.36)	$	1.87	$	2.22

Liquidity and Capital Resources

(Dollars in thousands, unless otherwise noted)

Liquidity

We believe that cash balances and operating cash flows, together with available capacity under our credit agreement, as utilized in the third quarter of 2024, will provide adequate funds to support our current short-term operating objectives as well as our longer-term strategic plans, subject to the risks and uncertainties outlined below, in our "Note Regarding Forward-Looking Statements" above, and in the risk factors previously disclosed in Item 1A of Part I of our 2023 Form 10-K. Our principal source of liquidity is our cash flow generated from operating activities, which is expected to provide us with the ability to meet the majority of our short-term funding requirements. Our cash flows are affected by capital requirements and production volume, which may be materially impacted by unanticipated events such as unplanned downtime, material disruptions at our production facilities, the prices of our raw materials, general economic and industry trends and customer demand. The Company applies a proactive and disciplined approach to working capital management to optimize cash flow and to enable capital allocation options in support of the Company’s strategy. We utilize supply chain financing and trade receivables discount arrangements with third-party financial institutions which optimize terms and conditions related to accounts receivable and accounts payable in order to enhance liquidity and enable us to efficiently manage our working capital needs. Although we continue to optimize supply chain financing and trade receivable programs in the ordinary course, our utilization of these arrangements has not had a material impact on our liquidity. In addition, we monitor the third-party depository institutions that hold our cash and cash equivalents. Our emphasis is primarily on the safety of principal and secondarily on maximizing yield on those funds. We diversify our cash and cash equivalents among counterparties to minimize exposure to any one of these entities.

On a recurring basis, our primary future cash needs will be centered on operating activities, working capital, capital expenditures, dividends and liquidity reflecting disciplined capital deployment. Capital expenditures are deployed for various ongoing investments and initiatives to improve reliability, yield and quality, expand production capacity and comply with health, safety and environmental ("HSE") regulations. We believe that our future cash from operations, cash on hand and available capacity under our credit agreement, as well as our access to credit and capital markets, will provide adequate resources to fund our expected operating and financing needs and obligations. Our ability to fund our capital needs, however, will depend on our ongoing ability to generate cash from operations and access to credit and capital markets, both of which are subject to the risk factors previously disclosed in Item 1A of Part I of our 2023 Form 10-K, as well as general economic, financial, competitive, regulatory and other factors that are beyond our control.

As of the end of the third quarter of 2024, the Company had approximately $17.3 million of cash on hand with approximately $284 million of additional capacity available under the revolving credit facility. The Company’s Consolidated Leverage Ratio financial covenant of its credit facility allows it to net up to $75 million of cash with debt. Capital expenditures are expected to be approximately $135 million to $140 million in 2024 compared to $107 million in 2023, reflecting refined execution timing

to address critical enterprise risk mitigation and growth projects including our SUSTAIN (Sustainable U.S. Sulfate to Accelerate Increased Nutrition) program.

We assumed from Honeywell International Inc. ("Honeywell") all HSE liabilities and compliance obligations related to the past and future operations of our current business as of the spin-off, as well as all HSE liabilities associated with the three manufacturing locations assumed from Honeywell that are used in our current operations, including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to have a material adverse effect on the Company's consolidated financial position or results of operations.

We expect that our primary cash requirements for 2024 will be to fund costs associated with ongoing operations, capital expenditures, and amounts related to other contractual obligations.

The Company made no cash contributions to the defined benefit pension plan during the nine months ended September 30, 2024 and does not expect to make cash contributions during the fourth quarter of 2024. Additional contributions may be made in future years sufficient to satisfy pension funding requirements in those periods.

The Company's Board of Directors (the "Board") has authorized share repurchase programs to repurchase shares of the Company's common stock as follows:


Date of Authorization	Authorized Amount (millions)		Authorized Amount Remaining as of September 30, 2024 (millions)
May 4, 2018	$	75.0	$	—
February 22, 2019	75.0		—
February 17, 2023	75.0		62.0
Totals	$	225.0	$	62.0

Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Exchange Act, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time. The par value of the shares repurchased is applied to Treasury stock and the excess of the purchase price over par value is applied to Additional paid-in capital.

As of September 30, 2024, the Company has repurchased a total of 6,252,129 shares of common stock life-to-date, including 1,006,673 shares withheld to cover tax withholding obligations in connection with the vesting of awards, for an aggregate of $192.4 million at a weighted average market price of $30.78 per share. As of September 30, 2024, $62.0 million remained available for share repurchases under the current authorization. During the period October 1, 2024 through October 25, 2024, no additional shares were repurchased for tax withholding obligations or under the currently authorized repurchase program.

As of September 30, 2024, the Company did not have any off-balance sheet arrangements as described in Instruction 8 to Item 303(b) of Regulation S-K and did not have any material changes in the commitments or contractual obligations detailed in the Company's 2023 Form 10-K (see Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" under "Liquidity and Capital Resources - Liquidity"). The Company has not guaranteed any debt or commitments of other entities or entered into any options on non-financial assets.

Dividends

The Company commenced the declaration of dividends on September 28, 2021.

Dividends announced during 2024 are as follows:

Date of Announcement

Date of Record

Date Payable

Dividend per Share

Total Approximate Dividend Amount ($M)

11/1/2024

11/12/2024

11/26/2024

$0.16

$4.3

8/2/2024

8/13/2024

8/27/2024

$0.16

$4.3

5/3/2024

5/14/2024

5/28/2024

$0.16

$4.3

2/16/2024

3/4/2024

3/18/2024

$0.16

$4.3

The timing, declaration, amount and payment of future dividends to stockholders, if any, will fall within the discretion of our Board. Holders of shares of our common stock will be entitled to receive dividends when, and if, declared by our Board at its discretion out of funds legally available for that purpose, subject to the terms of our indebtedness, the preferential rights of any preferred stock that may be outstanding, legal requirements, regulatory constraints, industry practice and other factors that our Board deems relevant.

Credit Agreement

On September 30, 2016, the Company as the borrower, entered into a Credit Agreement with Bank of America, as administrative agent (the "Original Credit Agreement"), which was amended on February 21, 2018 (the "First Amended and Restated Credit Agreement"), and further amended on February 19, 2020 (the “Second Amended and Restated Credit Agreement”). The Second Amended and Restated Credit Agreement had a five-year term with a scheduled maturity date of February 21, 2023.

On October 27, 2021, the Company completed a refinancing of the Second Amended and Restated Credit Agreement by entering into a new Credit Agreement (the “Credit Agreement”), among the Company, the lenders party thereto, the swing line lenders party thereto, the letter of credit issuers party thereto and Truist Bank, as administrative agent, which provides for a new senior secured revolving credit facility in an aggregate principal amount of $500 million (the “Revolving Credit Facility”).

Borrowings under the Revolving Credit Facility are subject to customary borrowing conditions.

The Revolving Credit Facility has a scheduled maturity date of October 27, 2026. The Credit Agreement permits the Company to utilize up to $40 million of the Revolving Credit Facility for the issuance of letters of credit and up to $40 million for swing line loans. The Company has the option to establish a new class of term loans and/or increase the amount of the Revolving Credit Facility in an aggregate principal amount for all such incremental term loans and increases of the Revolving Credit Facility of up to the sum of (x) $175 million plus (y) an amount such that the Company’s Consolidated First Lien Secured Leverage Ratio (as defined in the Credit Agreement) would not be greater than 2.75 to 1.00, in each case, to the extent that any one or more lenders, whether or not currently party to the Credit Agreement, commits to be a lender for such amount or any portion thereof.

With the cessation of LIBOR on June 30, 2023 and subject to the First Amendment to the Credit Agreement, dated as of June 27, 2023, the Eurodollar Rate was replaced with the Adjusted Term SOFR as an alternative benchmark rate for purposes of the Credit Agreement. The transition was effective July 1, 2023. Borrowings under the Credit Agreement bear interest at a rate equal to either the sum of a base rate plus a margin ranging from 0.25% to 1.25% or the sum of an Adjusted Term SOFR rate plus a margin ranging from 1.25% to 2.25%, with either such margin varying according to the Company’s Consolidated Leverage Ratio (as defined in the Credit Agreement). The Company is also required to pay a commitment fee in respect of unused commitments under the Revolving Credit Facility, if any, at a rate ranging from 0.15% to 0.35% per annum depending on the Company’s Consolidated Leverage Ratio. In conjunction with the cessation of LIBOR, as of July 1, 2023, the applicable margin under the Credit Agreement was 0.25% for base rate loans and 1.25% for Adjusted Term SOFR loans and the applicable commitment fee rate was 0.15% per annum.

Substantially all tangible and intangible assets of the Company and its domestic subsidiaries are pledged as collateral to secure the Company's obligations under the Credit Agreement.

The Credit Agreement contains customary covenants limiting the ability of the Company and its subsidiaries to, among other things, pay cash dividends, incur debt or liens, redeem or repurchase stock of the Company, enter into transactions with affiliates, make investments, make capital expenditures, merge or consolidate with others or dispose of assets. The Credit Agreement also contains financial covenants that require the Company to maintain a Consolidated Interest Coverage Ratio (as defined in the Credit Agreement) of not less than 3.00 to 1.00 and to maintain a Consolidated Leverage Ratio of (i) 4.00 to 1.00 or less for the fiscal quarter ending December 31, 2021, through and including the fiscal quarter ending September 30, 2023 and

(ii) 3.75 to 1.00 or less for each fiscal quarter thereafter (subject to the Company’s option to elect a consolidated leverage ratio increase in connection with certain acquisitions). If the Company does not comply with the covenants in the Credit Agreement, the lenders may, subject to customary cure rights, require the immediate payment of all amounts outstanding under the Revolving Credit Facility. We were in compliance with all of our covenants at September 30, 2024 and through the date of the filing of this Form 10-Q.

We had a borrowed balance of $170 million under the Revolving Credit Facility at December 31, 2023. We borrowed an incremental net amount of $45 million during the nine months ended September 30, 2024, bringing the balance under the Revolving Credit Facility to $215 million, and available credit for use of approximately $284 million as of September 30, 2024. We expect that Cash provided by operating activities will fund future interest payments on the Company's outstanding indebtedness.

Cash Flow Summary


	Nine Months Ended September 30,
	2024		2023
Cash provided by (used for):
Operating activities	$	71,248	$	57,381
Investing activities	(105,426)		(71,429)
Financing activities	21,708		5,173
Net change in cash and cash equivalents	$	(12,470)	$	(8,875)

Cash provided by operating activities increased by $13.9 million for the nine months ended September 30, 2024 versus the prior year period due primarily to (i) an $18.8 million favorable cash impact from accrued liabilities due primarily to the timing of payments and accruals during the nine months ended September 30, 2024 related to incentive-based compensation and other accrued liabilities compared to the prior year period and (ii) a $9.7 million favorable cash impact from working capital (comprised of Accounts and other receivables, Inventories, Accounts payable and Deferred income and customer advances) with a $44.4 million unfavorable cash impact from working capital for the nine months ended September 30, 2024 compared to a $54.0 million unfavorable cash impact in the prior year period due primarily to the favorable impact of Deferred income and customer advances, Inventory and Accounts payable partially offset by Accounts and other receivables. These net favorable impacts were partially offset by a $15.9 million decrease in Net income.

Cash used for investing activities increased by $34.0 million for the nine months ended September 30, 2024 versus the prior year period due primarily to higher cash payments for capital expenditures of approximately $30.3 million during the current year period primarily reflecting increased spend on replacement maintenance and enterprise programs.

Cash provided by financing activities increased by $16.5 million for the nine months ended September 30, 2024 versus the prior year period due primarily to net borrowings of $45.0 million during the nine months ended September 30, 2024 compared to net borrowings of $55.0 million during the prior year period, partially offset by payments for share repurchases of $10.4 million during the nine months ended September 30, 2024 compared to $37.7 million during the prior year period. Cash paid for dividends was relatively unchanged year-over-year.

Capital Expenditures

(Dollars in thousands, unless otherwise noted)

Our operations are capital intensive, requiring ongoing investments that have consisted, and are expected to continue to consist, primarily of capital expenditures required to maintain and improve equipment reliability, expand production output, further improve mix, yield and cost position, and comply with environmental and safety regulations.

The following table summarizes ongoing and expansion capital expenditures:


	Nine Months Ended September 30, 2024
Capital expenditures in Accounts payable at December 31, 2023	$	22,660
Purchases of property, plant and equipment	91,731
Less: Capital expenditures in Accounts payable at September 30, 2024	(15,018)
Cash paid for capital expenditures	$	99,373

For 2024, we expect our total capital expenditures to be approximately $135 million to $140 million compared to $107 million in 2023, reflecting refined execution timing to address critical enterprise risk mitigation and growth projects including our SUSTAIN (Sustainable U.S. Sulfate to Accelerate Increased Nutrition) program.

Critical Accounting Policies and Estimates

The preparation of our Condensed Consolidated Financial Statements in accordance with U.S. GAAP is based on the selection and application of accounting policies that require us to make significant estimates and assumptions about the effects of matters that are inherently uncertain. We consider these accounting policies to be critical to the understanding of our Condensed Consolidated Financial Statements. For a full description of our critical accounting policies, refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our 2023 Form 10-K. While there have been no material changes to our critical accounting policies, or the methodologies or assumptions we apply under them since the filing of the 2023 Form 10-K, we continue to monitor such methodologies and assumptions.

Recent Accounting Pronouncements

See “Note 2. Recent Accounting Pronouncements” to the Condensed Consolidated Financial Statements included in Part I. Item 1 of this Form 10-Q.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk

Our exposure to risk based on changes in interest rates during the nine-month period ended September 30, 2024 relates primarily to the Revolving Credit Facility. The Revolving Credit Facility bears interest at floating rates. For variable rate debt, interest rate changes generally do not affect the fair market value of such debt assuming all other factors remain constant but do impact future earnings and cash flows. Accordingly, we may be exposed to interest rate risk on borrowings under the Credit Agreement.

Based on current borrowing levels at September 30, 2024, a 25-basis point fluctuation in interest rates for the nine months ended September 30, 2024 would have resulted in an increase or decrease to our interest expense of approximately $0.5 million.

See “Note 12. Derivative and Hedging Instruments” to the Consolidated Financial Statements included in Item 8 of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 for a discussion relating to credit and market, commodity price and interest rate risk management.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud have been, or will be, detected.

Our Chief Executive Officer and Chief Financial Officer, with the assistance of other members of our management, conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective at a reasonable assurance level as of September 30, 2024, the end of the period covered by this quarterly report.

Changes in Internal Control over Financial Reporting

Management has not identified any change in the Company's internal control over financial reporting that occurred during the quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we are involved in litigation relating to claims arising outside of the ordinary course of our business operations. We are not a party to, and, to our knowledge, there are no pending claims or actions against us, the ultimate disposition of which could be expected to have a material adverse effect on our consolidated financial position, results of operations or operating cash flows.

ITEM 1A. RISK FACTORS

There have been no material changes to our risk factors as previously disclosed in Item 1A of Part I of the Company’s 2023 Form 10-K, which are hereby incorporated by reference.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On May 4, 2018, the Company announced that the Board authorized a share repurchase program of up to $75 million of the Company’s common stock. On February 22, 2019, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity authorized under the May 2018 share repurchase program. On February 17, 2023, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity available under the previously approved share repurchase program. Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Exchange Act, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The repurchase program has no expiration date and may be modified, suspended or discontinued at any time.

The below table sets forth the repurchases of Company common stock, by month, for the quarter ended September 30, 2024. During the quarter ended September 30, 2024, no additional shares were purchased under our share repurchase program and 1,948 shares were withheld to cover tax withholding obligations in connection with the vesting of equity awards.

ISSUER PURCHASES OF EQUITY SECURITIES


Period		Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plan	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plan
July 2024	(1)	1,933	$	21.63	—	$	61,957,898
August 2024		—	—		—	61,957,898
September 2024	(2)	15	26.93		—	61,957,898
Total		1,948	$	21.68	—

(1) Total number of shares purchased includes 1,933 shares covering tax withholding obligations in connection with the vesting of equity awards

(2) Total number of shares purchased includes 15 shares covering tax withholding obligations in connection with the vesting of equity awards

During the period October 1, 2024 through October 25, 2024, no additional shares were repurchased for tax withholding obligations or under the currently authorized repurchase program.

ITEM 5. OTHER INFORMATION

Insider Rule 10b5-1 Trading Plans

On September 13, 2024, Michael Preston, who served as the Company’s Senior Vice President and Chief Financial Officer until October 1, 2024, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of 43,030 shares. Mr. Preston’s plan will expire on February 28, 2025.

ITEM 6. EXHIBITS


Exhibit						Description
3.1						Amended and Restated Certificate of Incorporation of AdvanSix Inc. (conformed copy) (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q filed on August 1, 2019).
3.2						Amended and Restated By-laws of AdvanSix Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on June 20, 2023).
10.1						Offer of Employment Letter between AdvanSix Inc. and Siddharth Manjeshwar, dated September 12, 2024 †
31.1						Rule 13a-14(a)/15d-14(a) Certification of the Company’s Principal Executive Officer.
31.2						Rule 13a-14(a)/15d-14(a) Certification of the Company’s Principal Financial Officer.
32.1						Section 1350 Certification of the Company’s Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the SEC nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
32.2						Section 1350 Certification of the Company’s Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the SEC nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
101.INS						Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCH						Inline XBRL Taxonomy Extension Schema Document
101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB						Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase Document
104						Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101)

† Indicates management contract or compensatory plan.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	ADVANSIX INC.

Date: November 1, 2024	By:	/s/ Siddharth Manjeshwar
		Siddharth Manjeshwar
		Senior Vice President and Chief Financial Officer

Exhibit 10.1

September 12, 2024

Sidd Manjeshwar

Dear Sidd,

Congratulations! I am pleased to confirm the details of our offer to you for the position of Senior Vice President and Chief Financial Officer with AdvanSix Inc. (the “Company”), located in Parsippany, New Jersey.

In connection with your new role, you will be entitled to the following compensation and benefits package:

OFFER DETAILS

Base Salary

Your annual base salary will be $525,000. The Company conducts annual performance reviews and your performance rating, together with funding availability based on Company performance, will determine the amount of your annual salary increase, if any. You will first be eligible for merit consideration in March 2025 during the 2024 year-end cycle.

Short-Term Incentive Program

This position is eligible for participation in the Short-Term Incentive Program (“STIP”) for executive officers as may be in effect from time to time, subject to the terms and conditions of the STIP. For full year 2024 (payable in March 2025), your initial target incentive compensation opportunity under the STIP will be 70% of your annual base salary,and shall be subject to proration based on your start date. Your actual incentive payment amount may be more or less than such target incentive amount based on Company performance and your personal performance. The terms of any annual incentive program established under the STIP, including future target incentive compensation opportunities as a percentage of your annual base salary, are subject to the discretion of the Company’s Compensation & Leadership Development Committee.

Long-Term Incentive Program

This position is eligible for participation in the Long-Term Incentive Program (“LTIP”) for executive officers, as may be in effect from time to time. For the 2025 cycle, your initial LTIP target award value will be $800,000. The terms of the LTIP and the size and mix of the 2025 LTIP award and any future LTIP awards are all subject to the discretion of the Company’s Compensation Committee. The terms of all LTIP awards will be governed by the terms of the applicable stock plan and the applicable award agreements.

Executive Benefits

For your new role, your benefits will include four weeks of vacation, accrued as outlined in our paid time off policies, participation in our Executive Severance Policy and Deferred Compensation Plan, Executive Health Screening, and Excess Liability Insurance coverage, in each case as provided to other executive officers of the Company. You will be eligible for employee benefits under the specific terms of these benefit plans.

Sign-On Bonus

You are eligible for a sign-on bonus of $25,000 USD, subject to applicable taxes. If you leave or your employment is terminated prior to completing two years of employment, you will be required to pay the full sign-on bonus amount back to the Company.

Sign-On Long-Term Incentive Award

You are eligible for a sign-on equity award in the form of restricted stock units (“RSUs”) with an award value of $800,000, to be issued as soon as practicable following your start date, subject to your continued employment. The RSUs will vest on the third anniversary of the grant date, assuming your continued employment in good standing with the Company on such vesting date, and subject to the terms and conditions of the award agreement.

Stock Ownership Guidelines

As an executive officer of the Company, you will be required to hold 3x your annual base salary in Company shares in accordance with the Company’s Stock Ownership Guidelines, which may be amended from time to time by the Board of Directors or the Compensation Committee.

Intellectual Property and Non-Competition Agreement

By accepting this offer, you represent that you are not under any obligation or covenant to any former employer or any person, firm or corporation, which would prevent, limit or impair in any way the performance by you of your duties as an employee of the Company. You have also provided to the Company a true and complete copy of any non-competition and/or non-solicitation obligation or agreement to which you may be subject.

You agree not to: (1) use in connection with your employment with the Company any confidential or proprietary information which you have acquired in connection with any former employment or reveal or disclose to the Company or any Company employees, agents, representatives or vendors, any confidential or proprietary information which you have acquired in connection with any former employment; or (2) directly or indirectly solicit or attempt to solicit for hire any employee of any prior employer or directly or indirectly interfere with any customer or vendor relationship of any prior employer, in each case, in breach or violation of any existing covenant or obligation to which you may be subject and for the time period specified in any such covenant or obligation. You acknowledge that this policy and practice of the Company is to be strictly followed and adhered to by you. You also agree that you have not taken and do not have in your possession any confidential information of a prior employer and have returned to your prior employer any confidential information which was in your possession.

As a condition of this employment offer, you agree that you will sign (i) the Employee Agreement relating to Trade Secrets, Proprietary and Confidential information, and (ii) the Noncompete Agreement for executive officers that prohibits you from working for a Company competitor in any capacity for a period of two years following the termination for any reason of your employment.

Onboarding

Separately you will be provided our standard pre-employment requirements, which this offer letter is conditioned upon and are to be completed prior to your start date.

D&O Questionnaire

As an executive officer, this offer is conditioned upon the Company’s review and acceptance of the responses to your Director & Officer Questionnaire.

Background Check and Drug Screen

You represent that the information (written or oral) provided to the Company by you or your representatives in connection with obtaining employment or in connection with your former employments, work history, circumstances of leaving your former employments and educational background is true and complete.

This offer is conditioned upon you passing a background check and drug screen before you start work. Details regarding next steps for drug screen and background check will follow in a separate email once you have accepted the written offer.

You can review the Drugs & Alcohol in the Workplace Policy when you complete pre-employment information. Please ensure you complete the drug screen within the 30 days prior to your start date.

ACCEPTANCE OF OFFER

Please indicate your acceptance of this offer by signing this letter in the space provided and returning it to me.

If you have any questions or need any further information about our offer, please contact me or Kelly Slieter, our Senior Vice President and Chief Human Resources Officer.

Congratulations,

/s/ Erin N. Kane

Erin N. Kane

President and Chief Executive Officer

AdvanSix Inc.

Read and Accepted:

/s/ Sidd Manjeshwar September 12, 2024

Sidd Manjeshwar Date

All businesses experience changing conditions. We reserve the right to change work assignments, reporting relationships and staffing levels to meet business needs, and your employment with the Company will be on an "at will" basis. This means that there is no guarantee of employment for any specific period, and either you or the Company can terminate your employment at any time.

Exhibit 31.1

CERTIFICATIONS

I, Erin N. Kane, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of AdvanSix Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2024


			/s/ Erin N. Kane
			Erin N. Kane
			President and Chief Executive Officer

Exhibit 31.2

CERTIFICATIONS

I, Siddharth Manjeshwar, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of AdvanSix Inc.;

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2024


			/s/ Siddharth Manjeshwar
			Siddharth Manjeshwar
			Chief Financial Officer

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AdvanSix Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of her knowledge:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 1, 2024


			/s/ Erin N. Kane
			Erin N. Kane
			President and Chief Executive Officer

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 1, 2024


			/s/ Siddharth Manjeshwar
			Siddharth Manjeshwar
			Chief Financial Officer

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2024	Oct. 25, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	1-37774
Entity Registrant Name	AdvanSix Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-2525089
Entity Address, Address Line One	300 Kimball Drive
Entity Address, Address Line Two	Suite 101
Entity Address, City or Town	Parsippany
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07054
City Area Code	973
Local Phone Number	526-1800
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ASIX
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,731,009
Amendment Flag	false
Entity Central Index Key	0001673985
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Sales	$ 398,187	$ 322,907	$ 1,188,495	$ 1,151,391
Costs, expenses and other:
Costs of goods sold	340,885	314,785	1,046,860	1,004,844
Selling, general and administrative expenses	24,265	21,585	72,290	70,711
Interest expense, net	2,924	2,075	9,137	5,296
Other non-operating (income) expense, net	368	(5,485)	1,808	(6,918)
Total costs, expenses and other	368,442	332,960	1,130,095	1,073,933
Income (loss) before taxes	29,745	(10,053)	58,400	77,458
Income tax expense (benefit)	7,479	(2,076)	14,603	17,753
Net income (loss)	$ 22,266	$ (7,977)	$ 43,797	$ 59,705
Earnings per common share
Basic (in dollars per share)	$ 0.83	$ (0.29)	$ 1.63	$ 2.18
Diluted (in dollars per share)	$ 0.82	$ (0.29)	$ 1.61	$ 2.12
Weighted average common shares outstanding
Basic (in shares)	26,790,752	27,209,521	26,836,114	27,433,851
Diluted (in shares)	27,204,714	27,209,521	27,209,680	28,193,721

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 22,266	$ (7,977)	$ 43,797	$ 59,705
Foreign exchange translation adjustment	(24)	197	(66)	39
Cash-flow hedges	0	0	7	(150)
Other comprehensive income (loss), net of tax	(24)	197	(59)	(111)
Comprehensive income (loss)	$ 22,242	$ (7,780)	$ 43,738	$ 59,594

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 17,298	$ 29,768
Accounts and other receivables – net	149,058	165,393
Inventories – net	213,434	211,831
Taxes receivable	375	1,434
Other current assets	15,608	11,378
Total current assets	395,773	419,804
Property, plant and equipment – net	892,574	852,642
Operating lease right-of-use assets	90,740	95,805
Goodwill	56,192	56,192
Intangible assets	43,906	46,193
Other assets	31,050	25,384
Total assets	1,510,235	1,496,020
Current liabilities:
Accounts payable	207,272	259,068
Accrued liabilities	55,783	44,086
Income taxes payable	435	8,033
Operating lease liabilities – short-term	30,135	32,053
Deferred income and customer advances	1,517	15,678
Total current liabilities	295,142	358,918
Deferred income taxes	154,690	151,059
Operating lease liabilities – long-term	60,793	63,961
Line of credit – long-term	215,000	170,000
Postretirement benefit obligations	7,048	3,660
Other liabilities	11,154	9,185
Total liabilities	743,827	756,783
COMMITMENTS AND CONTINGENCIES (Note 9)
STOCKHOLDERS' EQUITY
Common stock, par value $0.01; 200,000,000 shares authorized; 32,982,868 shares issued and 26,730,739 outstanding at September 30, 2024; 32,598,946 shares issued and 26,750,471 outstanding at December 31, 2023	330	326
Preferred stock, par value $0.01; 50,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023	0	0
Treasury stock at par (6,252,129 shares at September 30, 2024; 5,848,475 shares at December 31, 2023)	(63)	(58)
Additional paid-in capital	134,735	138,046
Retained earnings	635,609	605,067
Accumulated other comprehensive loss	(4,203)	(4,144)
Total stockholders' equity	766,408	739,237
Total liabilities and stockholders' equity	$ 1,510,235	$ 1,496,020

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	32,982,868	32,598,946
Common stock, shares outstanding (in shares)	26,730,739	26,750,471
Preferred stock par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Treasury stock (in shares)	6,252,129	5,848,475

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net income	$ 43,797	$ 59,705
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	57,197	54,337
Loss on disposal of assets	415	939
Deferred income taxes	3,638	1,069
Stock-based compensation	5,963	5,840
Amortization of deferred financing fees	464	464
Operational asset adjustments	1,200	(4,472)
Changes in assets and liabilities, net of business acquisitions:
Accounts and other receivables	15,069	42,185
Inventories	(1,603)	(14,082)
Taxes receivable	1,059	8,273
Accounts payable	(43,687)	(50,123)
Income taxes payable	(7,598)	2,136
Accrued liabilities	10,988	(7,787)
Deferred income and customer advances	(14,161)	(32,015)
Other assets and liabilities	(1,493)	(9,088)
Net cash provided by operating activities	71,248	57,381
Cash flows from investing activities:
Expenditures for property, plant and equipment	(99,373)	(69,025)
Other investing activities	(6,053)	(2,404)
Net cash used for investing activities	(105,426)	(71,429)
Cash flows from financing activities:
Borrowings from line of credit	311,500	371,000
Payments of line of credit	(266,500)	(316,000)
Principal payments of finance leases	(762)	(698)
Dividend payments	(12,858)	(12,354)
Purchase of treasury stock	(10,427)	(37,651)
Issuance of common stock	755	876
Net cash provided by financing activities	21,708	5,173
Net change in cash and cash equivalents	(12,470)	(8,875)
Cash and cash equivalents at beginning of period	29,768	30,985
Cash and cash equivalents at the end of period	17,298	22,110
Supplemental non-cash investing activities:
Capital expenditures included in accounts payable	15,018	21,188
Supplemental cash activities:
Cash paid for interest	7,711	4,998
Cash paid for income taxes	$ 19,019	$ 7,037

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Treasury Stock	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2022		31,977,593
Beginning balance at Dec. 31, 2022	$ 738,180	$ 320	$ 174,585	$ 567,517	$ (45)	$ (4,197)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	34,954			34,954
Comprehensive income
Foreign exchange translation adjustments	(33)					(33)
Cash-flow hedges	(150)					(150)
Other comprehensive (loss) income, net of tax	(183)					(183)
Issuance of common stock (in shares)		555,249
Issuance of common stock	622	$ 5	617
Purchase of treasury stock	(13,499)		(13,496)		(3)
Stock-based compensation	2,013		2,013
Dividends	(4,020)		112	(4,132)
Ending balance (in shares) at Mar. 31, 2023		32,532,842
Ending balance at Mar. 31, 2023	758,067	$ 325	163,831	598,339	(48)	(4,380)
Beginning balance (in shares) at Dec. 31, 2022		31,977,593
Beginning balance at Dec. 31, 2022	738,180	$ 320	174,585	567,517	(45)	(4,197)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	59,705
Comprehensive income
Foreign exchange translation adjustments	39
Cash-flow hedges	(150)
Ending balance (in shares) at Sep. 30, 2023		32,597,015
Ending balance at Sep. 30, 2023	754,485	$ 326	143,965	614,557	(55)	(4,308)
Beginning balance (in shares) at Mar. 31, 2023		32,532,842
Beginning balance at Mar. 31, 2023	758,067	$ 325	163,831	598,339	(48)	(4,380)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	32,728			32,728
Comprehensive income
Foreign exchange translation adjustments	(125)					(125)
Other comprehensive (loss) income, net of tax	(125)					(125)
Issuance of common stock (in shares)		45,020
Issuance of common stock	123	$ 1	122
Purchase of treasury stock	(14,886)		(14,881)		(5)
Stock-based compensation	2,436		2,436
Dividends	(3,984)		198	(4,182)
Ending balance (in shares) at Jun. 30, 2023		32,577,862
Ending balance at Jun. 30, 2023	774,359	$ 326	151,706	626,885	(53)	(4,505)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(7,977)			(7,977)
Comprehensive income
Foreign exchange translation adjustments	197					197
Cash-flow hedges	0
Other comprehensive (loss) income, net of tax	197					197
Issuance of common stock (in shares)		19,153
Issuance of common stock	131		131
Purchase of treasury stock	(9,266)		(9,264)		(2)
Stock-based compensation	1,391		1,391
Dividends	(4,350)		1	(4,351)
Ending balance (in shares) at Sep. 30, 2023		32,597,015
Ending balance at Sep. 30, 2023	$ 754,485	$ 326	143,965	614,557	(55)	(4,308)
Beginning balance (in shares) at Dec. 31, 2023	26,750,471	32,598,946
Beginning balance at Dec. 31, 2023	$ 739,237	$ 326	138,046	605,067	(58)	(4,144)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(17,396)			(17,396)
Comprehensive income
Foreign exchange translation adjustments	(15)					(15)
Cash-flow hedges	7					7
Other comprehensive (loss) income, net of tax	(8)					(8)
Issuance of common stock (in shares)		323,989
Issuance of common stock	426	$ 3	423
Purchase of treasury stock	(7,023)		(7,020)		(3)
Stock-based compensation	2,211		2,211
Dividends	(4,290)		163	(4,453)
Ending balance (in shares) at Mar. 31, 2024		32,922,935
Ending balance at Mar. 31, 2024	$ 713,157	$ 329	133,823	583,218	(61)	(4,152)
Beginning balance (in shares) at Dec. 31, 2023	26,750,471	32,598,946
Beginning balance at Dec. 31, 2023	$ 739,237	$ 326	138,046	605,067	(58)	(4,144)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	43,797
Comprehensive income
Foreign exchange translation adjustments	(66)
Cash-flow hedges	$ 7
Ending balance (in shares) at Sep. 30, 2024	26,730,739	32,982,868
Ending balance at Sep. 30, 2024	$ 766,408	$ 330	134,735	635,609	(63)	(4,203)
Beginning balance (in shares) at Mar. 31, 2024		32,922,935
Beginning balance at Mar. 31, 2024	713,157	$ 329	133,823	583,218	(61)	(4,152)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	38,927			38,927
Comprehensive income
Foreign exchange translation adjustments	(27)					(27)
Other comprehensive (loss) income, net of tax	(27)					(27)
Issuance of common stock (in shares)		36,653
Issuance of common stock	1	$ 1
Purchase of treasury stock	(3,362)		(3,360)		(2)
Stock-based compensation	2,193		2,193
Dividends	(4,292)		130	(4,422)
Ending balance (in shares) at Jun. 30, 2024		32,959,588
Ending balance at Jun. 30, 2024	746,597	$ 330	132,786	617,723	(63)	(4,179)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	22,266			22,266
Comprehensive income
Foreign exchange translation adjustments	(24)					(24)
Cash-flow hedges	0
Other comprehensive (loss) income, net of tax	(24)					(24)
Issuance of common stock (in shares)		23,280
Issuance of common stock	328		328
Purchase of treasury stock	(42)		(42)
Stock-based compensation	1,559		1,559
Dividends	$ (4,276)		104	(4,380)
Ending balance (in shares) at Sep. 30, 2024	26,730,739	32,982,868
Ending balance at Sep. 30, 2024	$ 766,408	$ 330	$ 134,735	$ 635,609	$ (63)	$ (4,203)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - shares	3 Months Ended						77 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024
Statement of Stockholders' Equity [Abstract]
Stock repurchased during period (in shares)	1,948	141,242	260,464	266,959	410,862	333,054	6,252,129

Organization, Operations and Basis of Presentation

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Organization, Operations and Basis of Presentation

Description of Business

Basis of Presentation

Certain prior period amounts have been reclassified for consistency with the current period presentation.

The Company's Board of Directors (the "Board") has authorized share repurchase programs to repurchase shares of the Company's common stock as follows:


Date of Authorization	Authorized Amount (millions)		Authorized Amount Remaining as of September 30, 2024 (millions)
May 4, 2018	$	75.0	$	—
February 22, 2019	75.0		—
February 17, 2023	75.0		62.0
Totals	$	225.0	$	62.0

Recent Accounting Pronouncements	9 Months Ended
Recent Accounting Pronouncements	Sep. 30, 2024
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recent Accounting Pronouncements – The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations. On December 13, 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this ASU require that public business entities, on an annual basis, disclose specific categories in the rate reconciliation and provide additional information for reconciling items that are equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate. The amendments also require that the Company disclose the following (net of refunds received): (1) the amount of income taxes paid disaggregated by federal (national), state, and foreign taxes and (2) the amount of income taxes paid disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than 5 percent of total income taxes paid. Additionally, the amendments in this update eliminate the requirement for all entities to disclose the nature and estimate of the range of the reasonably possible change in the unrecognized tax benefits balance in the next 12 months or to make a statement that an estimate of the range cannot be made, and remove the requirement to disclose the cumulative amount of each type of temporary difference when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries and corporate joint ventures. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption of the amendments in this update are permitted for annual financial statements that have not yet been issued. The Company is evaluating the pronouncement and does not expect adoption to have a material impact on the Company's consolidated financial position or results of operations. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this ASU require incremental disclosures about the Company's reportable segments, but do not change the definition of a segment or the guidance for determining reportable segments. The incremental disclosures should include (1) significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, (2) an amount for other segment items by reportable segment and a description of its composition, (3) profit or loss and assets currently required by Topic 280 in interim periods, (4) clarification if the CODM uses more than one measure of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources and (5) the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. The guidance is effective for public entities with fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Additionally, public entities should apply the amendments retrospectively to all prior periods presented in the financial statements, unless impractical. The Company is evaluating the pronouncement and does not expect adoption to have a material impact on the Company's consolidated financial position or results of operations.

Revenues

9 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Revenues

Revenue Recognition

The Company's revenue by product line, and related approximate percentage of total sales, for the three and nine months ended September 30, 2024 and 2023 were as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
Nylon	$	93,693	24%	$	86,056	27%	$	281,299	24%	$	278,381	24%
Caprolactam	76,338		19%	68,795		21%	219,117		18%	215,867		19%
Ammonium Sulfate *	107,668		27%	79,067		24%	332,604		28%	332,224		29%
Chemical Intermediates *	120,488		30%	88,989		28%	355,475		30%	324,919		28%
Total	$	398,187	100%	$	322,907	100%	$	1,188,495	100%	$	1,151,391	100%

The Company's revenues by geographic area, and related approximate percentage of total sales, for the three and nine months ended September 30, 2024 and 2023 were as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
United States	$	339,895	85%	$	264,858	82%	$	1,026,342	86%	$	953,392	83%
International	58,292		15%	58,049		18%	162,153		14%	197,999		17%
Total	$	398,187	100%	$	322,907	100%	$	1,188,495	100%	$	1,151,391	100%

Deferred Income and Customer Advances



Opening balance January 1, 2024	$	15,678
Additional cash advances	1,453
Less amounts recognized in revenues	(15,614)
Ending balance September 30, 2024	$	1,517

The Company expects to recognize as revenue the September 30, 2024 ending balance of Deferred income and customer advances within one year or less.

Earnings Per Share

9 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Earnings Per Share


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Basic
Net income (loss)	$	22,266	$	(7,977)	$	43,797	$	59,705
Weighted average common shares outstanding	26,790,752		27,209,521		26,836,114		27,433,851
EPS – Basic	$	0.83	$	(0.29)	$	1.63	$	2.18
Diluted
Dilutive effect of equity awards and other stock-based holdings	413,962		—		373,566		759,870
Weighted average common shares outstanding	27,204,714		27,209,521		27,209,680		28,193,721
EPS – Diluted	$	0.82	$	(0.29)	$	1.61	$	2.12


	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Options and stock equivalents	573,586	498,652	976,699	447,950

Dividend activity for the three and nine months ended September 30, 2024 and 2023 was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Cash dividends declared per share	$	0.16	$	0.16	$	0.48	$	0.45
Aggregate dividends paid to shareholders	$	4,276	$	4,349	$	12,858	$	12,354

Accounts and Other Receivables - Net

9 Months Ended

Sep. 30, 2024

Receivables [Abstract]

Accounts and Other Receivables - Net

Accounts and Other Receivables – Net


	September 30, 2024		December 31, 2023
Accounts receivables	$	142,598	$	155,267
Other	6,982		10,959
Total accounts and other receivables	149,580		166,226
Less – allowance for doubtful accounts	(522)		(833)
Total accounts and other receivables – net	$	149,058	$	165,393

Inventories

9 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

Inventories


	September 30, 2024		December 31, 2023
Raw materials	$	119,876	$	159,240
Work in progress	65,980		54,936
Finished goods	58,639		61,891
Spares and other	32,989		30,931
	277,484		306,998
Reduction to LIFO cost basis	(64,050)		(95,167)
Total inventories	$	213,434	$	211,831

The excess of replacement cost over the carrying value of total inventories subject to LIFO was $65.1 million and $65.3 million at September 30, 2024 and December 31, 2023, respectively.

Leases

9 Months Ended

Sep. 30, 2024

Leases [Abstract]

Leases

The components of lease expense were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Finance lease cost:
Amortization of right-of-use asset	$	269	$	237	$	776	$	675
Interest on lease liabilities	43		28		120		69
Total finance lease cost	312		265		896		744
Operating lease cost	10,305		12,032		32,789		34,873
Short-term lease cost	1,177		1,572		3,511		4,109

Total lease cost	$	11,794	$	13,869	$	37,196	$	39,726

Leases

The components of lease expense were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Finance lease cost:
Amortization of right-of-use asset	$	269	$	237	$	776	$	675
Interest on lease liabilities	43		28		120		69
Total finance lease cost	312		265		896		744
Operating lease cost	10,305		12,032		32,789		34,873
Short-term lease cost	1,177		1,572		3,511		4,109

Total lease cost	$	11,794	$	13,869	$	37,196	$	39,726

Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Goodwill

There was no change in the carrying amount of goodwill for the nine months ended September 30, 2024.

Finite-Lived Intangible Assets

Intangible assets subject to amortization were as follows:


	September 30, 2024						December 31, 2023
	Gross Carrying Amount		Accumulated Amortization		Net Book Value		Gross Carrying Amount		Accumulated Amortization		Net Book Value
Customer relationships	$	36,820	$	(5,190)	$	31,630	$	36,820	$	(3,760)	$	33,060
Licenses	18,451		(6,688)		11,763		18,451		(5,996)		12,455
Trade names	1,100		(587)		513		1,100		(422)		678
Total	$	56,371	$	(12,465)	$	43,906	$	56,371	$	(10,178)	$	46,193

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company is subject to a number of lawsuits, investigations and disputes, some of which may involve substantial amounts claimed, arising out of the conduct of the Company or other third-parties in the normal and ordinary course of business. A liability is recognized for any contingency that is probable of occurrence and reasonably estimable. The Company continually assesses the likelihood of adverse judgments or outcomes in these matters, as well as potential ranges of possible losses, based on an analysis of each matter with the assistance of legal counsel and, if applicable, other experts. Given the uncertainty inherent in such lawsuits, investigations and disputes, the Company does not believe it is possible to develop estimates of reasonably possible loss in excess of current accruals for these matters. Considering the Company’s past experience and existing accruals, the Company does not expect the outcome of these matters, either individually or in the aggregate, to have a material adverse effect on the Company’s consolidated financial position or results of operations. Potential liabilities are subject to change due to new developments, changes in settlement strategy or the impact of evidentiary requirements, which could cause the Company to pay damage awards or settlements (or become subject to equitable remedies) that could have a material adverse effect on the Company’s consolidated results of operations, balance sheet and/or operating cash flows in the periods recognized or paid. We assumed from Honeywell International Inc. ("Honeywell") all health, safety and environmental (“HSE”) liabilities and compliance obligations related to the past and future operations of our current business as of the spin-off, as well as all HSE liabilities associated with the three manufacturing locations assumed from Honeywell that are used in our current operations, including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to have a material adverse effect on the Company's consolidated financial position or results of operations.

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The provision (benefit) for income taxes was $7.5 million and ($2.1 million) for the three months ended September 30, 2024 and 2023, respectively, resulting in an effective tax rate of 25.1% and 20.7%, respectively. The provision for income taxes was $14.6 million and $17.8 million for the nine months ended September 30, 2024 and 2023, respectively, resulting in an effective tax rate of 25.0% and 22.9%, respectively. The Company’s provision (benefit) for income taxes in interim periods is computed by applying an estimated annual effective tax rate against Income before taxes for the period in addition to recording any tax effects of discrete items for the quarter. The Company’s effective tax rate for the three and nine months ended September 30, 2024 and 2023 differed from the U.S. federal statutory rate, due primarily to the impacts of state taxes and executive compensation deduction limitations, offset by tax credits and the foreign-derived intangible income deduction. In 2024, the Company recorded discrete tax adjustments related to the vesting of equity compensation, changes to state tax legislation, and return to provision adjustments related to the filing of the Company's 2023 U.S. federal income tax return which resulted in a net 3.3% increase to the quarterly effective tax rate and a net 1.5% increase to the year-to-date effective tax rate. Additionally for 2023, discrete tax adjustments relating to the vesting of equity compensation, changes in state tax legislation, and return to provision adjustments related to the filing of the Company's 2022 U.S. federal income tax return resulted in a net 4.4% increase to the quarterly effective tax rate and a net 1.6% decrease to the year-to-date effective tax rate.

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Financial and non-financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The pension plan assets are invested in collective investment trust funds. These investments are measured at fair value using the net asset value per share as a practical expedient. Investments valued using the net asset value method (NAV) (or its equivalent) practical expedient are excluded from the fair value hierarchy disclosure. The Company’s Condensed Consolidated Balance Sheets also include Cash and cash equivalents, Accounts receivable and Accounts payable all of which are recorded at amounts which approximate fair value. The Company also has assets that are required to be recorded at fair value on a non-recurring basis. These assets are evaluated when certain triggering events occur (including a decrease in estimated future cash flows) that indicate the asset should be evaluated for impairment which could result in such assets being measured at fair value. Goodwill must be evaluated at least annually. Our annual evaluation occurred on October 28, 2023 and we concluded that an impairment for goodwill did not occur.

Supplier Finance Program	9 Months Ended
Supplier Finance Program	Sep. 30, 2024
Payables and Accruals [Abstract]
Supplier Finance Program	Supplier Finance Programs The Company has entered into a supply chain finance program with a financial intermediary providing participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. AdvanSix’s responsibility is limited to making payments to the intermediary based upon payment terms negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. The Company’s payment terms with suppliers are consistent, regardless of whether a vendor participates in the supply chain finance program or not. All related agreements are terminable by either party upon at least 30 days’ notice. The total amount due to the financial intermediaries to settle supplier invoices under the supplier finance programs was approximately $15 million as of September 30, 2024 and approximately $17 million as of December 31, 2023. These amounts outstanding are included in Accounts payable

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events As announced on November 1, 2024, the Board declared a quarterly cash dividend of $0.16 per share on the Company's common stock, payable on November 26, 2024 to stockholders of record as of the close of business on November 12, 2024.

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net income	$ 22,266	$ 38,927	$ (17,396)	$ (7,977)	$ 32,728	$ 34,954	$ 43,797	$ 59,705

Insider Trading Arrangements	3 Months Ended	9 Months Ended
Insider Trading Arrangements	Sep. 30, 2024 shares	Sep. 30, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Michael Preston [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On September 13, 2024, Michael Preston, who served as the Company’s Senior Vice President and Chief Financial Officer until October 1, 2024, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of 43,030 shares. Mr. Preston’s plan will expire on February 28, 2025.
Name	Michael Preston
Title	Senior Vice President and Chief Financial Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 13, 2024
Arrangement Duration	168 days
Aggregate Available	43,030	43,030

Recent Accounting Pronouncements (Policies)	9 Months Ended
Recent Accounting Pronouncements (Policies)	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of September 30, 2024, and its results of operations for the three and nine months ended September 30, 2024 and 2023 and cash flows for the nine months ended September 30, 2024 and 2023. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"). All intercompany transactions have been eliminated. Certain prior period amounts have been reclassified for consistency with the current period presentation. It is our practice to establish actual quarterly closing dates using a predetermined fiscal calendar, which requires our businesses to close their books on a Saturday in order to minimize the potentially disruptive effects of quarterly closing on our business processes. Historically, the effects of this practice have generally not been significant to reported results for any quarter and only existed within a reporting year. In the event that differences in actual closing dates are material to year-over-year comparisons of quarterly or year-to-date results, we will provide the appropriate disclosures. Our actual closing dates for the three and nine months ended September 30, 2024 and 2023 were September 28, 2024 and September 30, 2023, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements – The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations. On December 13, 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this ASU require that public business entities, on an annual basis, disclose specific categories in the rate reconciliation and provide additional information for reconciling items that are equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate. The amendments also require that the Company disclose the following (net of refunds received): (1) the amount of income taxes paid disaggregated by federal (national), state, and foreign taxes and (2) the amount of income taxes paid disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than 5 percent of total income taxes paid. Additionally, the amendments in this update eliminate the requirement for all entities to disclose the nature and estimate of the range of the reasonably possible change in the unrecognized tax benefits balance in the next 12 months or to make a statement that an estimate of the range cannot be made, and remove the requirement to disclose the cumulative amount of each type of temporary difference when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries and corporate joint ventures. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption of the amendments in this update are permitted for annual financial statements that have not yet been issued. The Company is evaluating the pronouncement and does not expect adoption to have a material impact on the Company's consolidated financial position or results of operations. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this ASU require incremental disclosures about the Company's reportable segments, but do not change the definition of a segment or the guidance for determining reportable segments. The incremental disclosures should include (1) significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, (2) an amount for other segment items by reportable segment and a description of its composition, (3) profit or loss and assets currently required by Topic 280 in interim periods, (4) clarification if the CODM uses more than one measure of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources and (5) the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. The guidance is effective for public entities with fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Additionally, public entities should apply the amendments retrospectively to all prior periods presented in the financial statements, unless impractical. The Company is evaluating the pronouncement and does not expect adoption to have a material impact on the Company's consolidated financial position or results of operations.

Organization, Operations and Basis of Presentation (Tables)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Schedule of Authorized Share Repurchase Programs

The Company's Board of Directors (the "Board") has authorized share repurchase programs to repurchase shares of the Company's common stock as follows:


Date of Authorization	Authorized Amount (millions)		Authorized Amount Remaining as of September 30, 2024 (millions)
May 4, 2018	$	75.0	$	—
February 22, 2019	75.0		—
February 17, 2023	75.0		62.0
Totals	$	225.0	$	62.0

Revenues (Tables)

9 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The Company's revenue by product line, and related approximate percentage of total sales, for the three and nine months ended September 30, 2024 and 2023 were as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
Nylon	$	93,693	24%	$	86,056	27%	$	281,299	24%	$	278,381	24%
Caprolactam	76,338		19%	68,795		21%	219,117		18%	215,867		19%
Ammonium Sulfate *	107,668		27%	79,067		24%	332,604		28%	332,224		29%
Chemical Intermediates *	120,488		30%	88,989		28%	355,475		30%	324,919		28%
Total	$	398,187	100%	$	322,907	100%	$	1,188,495	100%	$	1,151,391	100%

The Company's revenues by geographic area, and related approximate percentage of total sales, for the three and nine months ended September 30, 2024 and 2023 were as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
United States	$	339,895	85%	$	264,858	82%	$	1,026,342	86%	$	953,392	83%
International	58,292		15%	58,049		18%	162,153		14%	197,999		17%
Total	$	398,187	100%	$	322,907	100%	$	1,188,495	100%	$	1,151,391	100%

Schedule of Deferred Income and Customer Advances

Below is a roll-forward of Deferred income and customer advances for the nine months ended September 30, 2024:



Opening balance January 1, 2024	$	15,678
Additional cash advances	1,453
Less amounts recognized in revenues	(15,614)
Ending balance September 30, 2024	$	1,517

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Schedule of Earnings Per Share

The details of the basic and diluted EPS calculations for the three and nine months ended September 30, 2024 and 2023 were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Basic
Net income (loss)	$	22,266	$	(7,977)	$	43,797	$	59,705
Weighted average common shares outstanding	26,790,752		27,209,521		26,836,114		27,433,851
EPS – Basic	$	0.83	$	(0.29)	$	1.63	$	2.18
Diluted
Dilutive effect of equity awards and other stock-based holdings	413,962		—		373,566		759,870
Weighted average common shares outstanding	27,204,714		27,209,521		27,209,680		28,193,721
EPS – Diluted	$	0.82	$	(0.29)	$	1.61	$	2.12

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The anti-dilutive common stock equivalents outstanding at the three and nine months ended September 30, 2024 and 2023 were as follows:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Options and stock equivalents	573,586	498,652	976,699	447,950

Schedule of Dividends Declared

Dividend activity for the three and nine months ended September 30, 2024 and 2023 was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Cash dividends declared per share	$	0.16	$	0.16	$	0.48	$	0.45
Aggregate dividends paid to shareholders	$	4,276	$	4,349	$	12,858	$	12,354

Accounts and Other Receivables - Net (Tables)

9 Months Ended

Sep. 30, 2024

Receivables [Abstract]

Schedule of Accounts and Other Receivables Net


	September 30, 2024		December 31, 2023
Accounts receivables	$	142,598	$	155,267
Other	6,982		10,959
Total accounts and other receivables	149,580		166,226
Less – allowance for doubtful accounts	(522)		(833)
Total accounts and other receivables – net	$	149,058	$	165,393

Inventories (Tables)

9 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

Schedule of Inventory, Current


	September 30, 2024		December 31, 2023
Raw materials	$	119,876	$	159,240
Work in progress	65,980		54,936
Finished goods	58,639		61,891
Spares and other	32,989		30,931
	277,484		306,998
Reduction to LIFO cost basis	(64,050)		(95,167)
Total inventories	$	213,434	$	211,831

Leases (Tables)

9 Months Ended

Sep. 30, 2024

Leases [Abstract]

Schedule of Components of Lease Expense

The components of lease expense were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Finance lease cost:
Amortization of right-of-use asset	$	269	$	237	$	776	$	675
Interest on lease liabilities	43		28		120		69
Total finance lease cost	312		265		896		744
Operating lease cost	10,305		12,032		32,789		34,873
Short-term lease cost	1,177		1,572		3,511		4,109

Total lease cost	$	11,794	$	13,869	$	37,196	$	39,726

Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

Intangible assets subject to amortization were as follows:


	September 30, 2024						December 31, 2023
	Gross Carrying Amount		Accumulated Amortization		Net Book Value		Gross Carrying Amount		Accumulated Amortization		Net Book Value
Customer relationships	$	36,820	$	(5,190)	$	31,630	$	36,820	$	(3,760)	$	33,060
Licenses	18,451		(6,688)		11,763		18,451		(5,996)		12,455
Trade names	1,100		(587)		513		1,100		(422)		678
Total	$	56,371	$	(12,465)	$	43,906	$	56,371	$	(10,178)	$	46,193

Organization, Operations and Basis of Presentation - Narrative (Details) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended						77 Months Ended
	Oct. 25, 2024 shares	Sep. 30, 2024 USD ($) manufacuringSite shares	Jun. 30, 2024 shares	Mar. 31, 2024 shares	Sep. 30, 2023 shares	Jun. 30, 2023 shares	Mar. 31, 2023 shares	Sep. 30, 2024 USD ($) manufacuringSite $ / shares shares	Dec. 31, 2023 USD ($)
Equity, Class of Treasury Stock [Line Items]
Number of manufacturing sites \| manufacuringSite		5						5
Checks outstanding \| $		$ 2.4						$ 2.4	$ 2.9
Stock repurchased during period (in shares) \| shares		1,948	141,242	260,464	266,959	410,862	333,054	6,252,129
Shares of common stock covering the tax withholding obligations (in shares) \| shares								1,006,673
Stock repurchased during period, value \| $								$ 192.4
Treasury stock acquired, weighted average cost per share (in dollars per share) \| $ / shares								$ 30.78
Authorized amount remaining \| $		$ 62.0						$ 62.0
Subsequent Event
Equity, Class of Treasury Stock [Line Items]
Shares of common stock covering the tax withholding obligations (in shares) \| shares	0

Organization, Operations and Basis of Presentation - Schedule of Authorized Share Repurchase Programs (Details) $ in Millions	Sep. 30, 2024 USD ($)
Equity, Class of Treasury Stock [Line Items]
Authorized Amount	$ 225.0
Authorized amount remaining	62.0
May 2018 Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Authorized Amount	75.0
Authorized amount remaining	0.0
February 2019 Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Authorized Amount	75.0
Authorized amount remaining	0.0
February 2023 Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Authorized Amount	75.0
Authorized amount remaining	$ 62.0

Revenues - Narrative (Details) - customer	3 Months Ended		9 Months Ended
Revenues - Narrative (Details) - customer	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Concentration Risk [Line Items]
Number of customers			400
Length of contract terms			We typically sell to customers under master service agreements, with primarily one-year terms, or by purchase orders.
10 Largest Customers \| Customer Concentration Risk \| Revenue from Contract with Customer
Concentration Risk [Line Items]
Concentration risk percentage	41.00%	41.00%	38.00%	39.00%
Shaw Industries Group Inc \| Customer Concentration Risk \| Revenue from Contract with Customer
Concentration Risk [Line Items]
Concentration risk percentage	10.00%	12.00%	9.00%	11.00%

Revenues - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Sales	$ 398,187	$ 322,907	$ 1,188,495	$ 1,151,391
Revenue from Contract with Customer \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	100.00%	100.00%	100.00%	100.00%
Revenue from Contract with Customer \| Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	100.00%	100.00%	100.00%	100.00%
United States
Disaggregation of Revenue [Line Items]
Sales	$ 339,895	$ 264,858	$ 1,026,342	$ 953,392
United States \| Revenue from Contract with Customer \| Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	85.00%	82.00%	86.00%	83.00%
International
Disaggregation of Revenue [Line Items]
Sales	$ 58,292	$ 58,049	$ 162,153	$ 197,999
International \| Revenue from Contract with Customer \| Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	15.00%	18.00%	14.00%	17.00%
Nylon
Disaggregation of Revenue [Line Items]
Sales	$ 93,693	$ 86,056	$ 281,299	$ 278,381
Nylon \| Revenue from Contract with Customer \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	24.00%	27.00%	24.00%	24.00%
Caprolactam
Disaggregation of Revenue [Line Items]
Sales	$ 76,338	$ 68,795	$ 219,117	$ 215,867
Caprolactam \| Revenue from Contract with Customer \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	19.00%	21.00%	18.00%	19.00%
Ammonium Sulfate Fertilizers
Disaggregation of Revenue [Line Items]
Sales	$ 107,668	$ 79,067	$ 332,604	$ 332,224
Ammonium Sulfate Fertilizers \| Restatement Adjustment
Disaggregation of Revenue [Line Items]
Sales		$ 5,500		$ 5,500
Ammonium Sulfate Fertilizers \| Revenue from Contract with Customer \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	27.00%	24.00%	28.00%	29.00%
Ammonium Sulfate Fertilizers \| Revenue from Contract with Customer \| Restatement Adjustment \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage		2.00%		2.00%
Chemical Intermediates
Disaggregation of Revenue [Line Items]
Sales	$ 120,488	$ 88,989	$ 355,475	$ 324,919
Chemical Intermediates \| Restatement Adjustment
Disaggregation of Revenue [Line Items]
Sales		$ (26,600)		$ (26,600)
Chemical Intermediates \| Revenue from Contract with Customer \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	30.00%	28.00%	30.00%	28.00%
Chemical Intermediates \| Revenue from Contract with Customer \| Restatement Adjustment \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage		(2.00%)		(2.00%)

Revenues - Schedule of Deferred Income and Customer Advances (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Change in Contract with Customer, Liability [Roll Forward]
Opening balance	$ 15,678
Additional cash advances	1,453
Less amounts recognized in revenues	(15,614)
Ending balance	$ 1,517

Earnings Per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Basic
Net income (loss)	$ 22,266	$ 38,927	$ (17,396)	$ (7,977)	$ 32,728	$ 34,954	$ 43,797	$ 59,705
Weighted average common shares outstanding (in shares)	26,790,752			27,209,521			26,836,114	27,433,851
EPS – Basic (in dollars per share)	$ 0.83			$ (0.29)			$ 1.63	$ 2.18
Diluted
Dilutive effect of equity awards and other stock-based holdings (in shares)	413,962			0			373,566	759,870
Weighted average common shares outstanding (in shares)	27,204,714			27,209,521			27,209,680	28,193,721
EPS – Diluted (in dollars per share)	$ 0.82			$ (0.29)			$ 1.61	$ 2.12

Earnings Per Share - Schedule of Antidilutive Common Stock Equivalents (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Options and stock equivalents (in shares)	573,586	498,652	976,699	447,950

Earnings Per Share - Schedule of Dividend Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Cash dividends declared per share (in dollars per share)	$ 0.16	$ 0.16	$ 0.48	$ 0.45
Aggregate dividends paid to shareholders	$ 4,276	$ 4,349	$ 12,858	$ 12,354

Accounts and Other Receivables - Net (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Receivables [Abstract]
Accounts receivables	$ 142,598	$ 155,267
Other	6,982	10,959
Total accounts and other receivables	149,580	166,226
Less – allowance for doubtful accounts	(522)	(833)
Total accounts and other receivables – net	$ 149,058	$ 165,393

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 119,876	$ 159,240
Work in progress	65,980	54,936
Finished goods	58,639	61,891
Spares and other	32,989	30,931
Inventory gross	277,484	306,998
Reduction to LIFO cost basis	(64,050)	(95,167)
Total inventories	$ 213,434	211,831
Percentage of FIFO inventory	8.00%
Excess of replacement or current costs over stated LIFO value	$ 65,100	$ 65,300

Leases - Schedule of Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Finance Lease Cost
Amortization of right-of-use asset	$ 269	$ 237	$ 776	$ 675
Interest on lease liabilities	43	28	120	69
Total finance lease cost	312	265	896	744
Operating lease cost	10,305	12,032	32,789	34,873
Short-term lease cost	1,177	1,572	3,511	4,109
Total lease cost	$ 11,794	$ 13,869	$ 37,196	$ 39,726

Leases - Narrative (Details) $ in Millions	Sep. 30, 2024 USD ($)
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	6 years
Operating Lease
Lessee, Lease, Description [Line Items]
Including lease not yet commenced	$ 93.1

Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 800	$ 800	$ 2,300	$ 2,300
Customer relationships \| U.S. Amines, Ltd. \| Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	15 years		15 years
Customer relationships \| U.S. Amines, Ltd. \| Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	20 years		20 years
Trade names \| U.S. Amines, Ltd.
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years		5 years

Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 56,371	$ 56,371
Accumulated Amortization	(12,465)	(10,178)
Net Book Value	43,906	46,193
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	36,820	36,820
Accumulated Amortization	(5,190)	(3,760)
Net Book Value	31,630	33,060
Licenses
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	18,451	18,451
Accumulated Amortization	(6,688)	(5,996)
Net Book Value	11,763	12,455
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,100	1,100
Accumulated Amortization	(587)	(422)
Net Book Value	$ 513	$ 678

Commitments and Contingencies (Details)	9 Months Ended
Commitments and Contingencies (Details)	Sep. 30, 2024 location
Commitments and Contingencies Disclosure [Abstract]
Number of manufacturing locations	3

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 7,479	$ (2,076)	$ 14,603	$ 17,753
Effective income tax rate	25.10%	20.70%	25.00%	22.90%
Discrete tax adjustment relating to vesting of equity compensation, percent			3.30%	4.40%
Discrete tax adjustment relating to changes in state tax legislation			1.50%	(1.60%)

Fair Value Measurements (Details)	Oct. 28, 2023 USD ($)
Fair Value Disclosures [Abstract]
Impairment for goodwill	$ 0

Supplier Finance Program (Details) - USD ($) $ in Millions	9 Months Ended
Supplier Finance Program (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Period of termination	30 days
Supplier finance program	$ 15	$ 17
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]	Accounts payable	Accounts payable

Subsequent Events (Details) - $ / shares		3 Months Ended		9 Months Ended
Subsequent Events (Details) - $ / shares	Nov. 01, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Subsequent Event [Line Items]
Cash dividends declared per share (in dollars per share)		$ 0.16	$ 0.16	$ 0.48	$ 0.45
Subsequent Event
Subsequent Event [Line Items]
Cash dividends declared per share (in dollars per share)	$ 0.16

AdvanSix (NYSE:ASIX)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

AdvanSix (NYSE:ASIX)
Historical Stock Chart
Von Dez 2023 bis Dez 2024

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

ASIX AdvanSix Inc

News AdvanSix Inc

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

ASIX AdvanSix Inc

News AdvanSix Inc

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen